BMJ Open

Clinical characteristics, prognosis, and risk prediction model for adverse outcomes in patients suspected of coronary artery diseases and no significant stenosis on angiography

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2024-092614
Article Type:	Original research
Date Submitted by the Author:	19-Aug-2024
Complete List of Authors:	Zhu, Lei; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Xue, Zheng-Kai; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Wu, Xue; University of California San Francisco, Institute for Global Health Sciences Zhang, JingKun; University of California San Francisco Hu, Su-Tao; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Zhang, Yu-Kun; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Gu, Tian-Shu; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Liu, Tong; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Rha, Seung-Woon; Korea University Guro Hospital, Cardiovascular Center Chen, Kang-Yin; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology
Keywords:	Angina Pectoris, Coronary heart disease < CARDIOLOGY, Prognosis

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Clinical characteristics, prognosis, and risk prediction model for adverse outcomes in patients suspected of coronary artery diseases and no significant stenosis on angiography

Authors: Lei Zhu[1], Zheng-Kai Xue[1], Xue Wu[2], Jing-Kun Zhang[3], Su-Tao Hu [1], Yu-Kun Zhang[1], Tian-Shu Gu[1], Tong Liu[1], Seung-Woon Rha[4], Kang-Yin Chen[1*]

Affiliations: [1] Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.

[2] Institute for Global Health Sciences, University of California, San Francisco, CA, USA

[3] Cardiovascular Research Institute, University of California San Francisco, CA, USA

[4] Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.

***Corresponding author:** Kang-Yin Chen, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China (chenkangyin@vip.126.com)

Word count: 2939

Abstract

Background and objectives

Although patients with suspected coronary artery disease and no significant stenosis on angiography are thought to have a better prognosis, some still experience adverse outcomes. This study aims to develop a predictive model for these adverse outcomes.

Methods

We retrospectively enrolled patients diagnosed with angina with nonobstructive coronary arteries (ANOCA) between January 2019 and June 2023, collecting relevant clinical data. We employed LASSO regression to select adverse prognostic risk factors, which were then integrated into a Cox proportional hazards regression model. Subsequently, we created a nomogram. Model performance was assessed for discrimination and calibration using the areas under the curve (AUC) and calibration plots, along with internal validation. The nomogram was utilized to categorize patients into high- and low-risk groups, and we compared their survival differences using the log-rank test.

Results

4,452 patients were included in the training cohort, and 1,482 in the testing cohort. The nomogram incorporated eight variables: age, hemoglobin, serum urea, serum sodium, ALT/AST ratio, NT-proBNP, left atrial diameter, and LVEF. It showed good predictive performance for 1-year, 2-year, and 3-year event-free survival probabilities in both the training cohorts (AUC 0.82, 0.90, and 0.89) and testing cohorts (AUC 0.75, 0.77, and 0.78). Calibration plots revealed close alignment between

predicted and actual event-free survival probabilities in both cohorts. Significant survival differences were observed among risk groups (log-rank $p < 0.0001$).

Conclusions

This study has successfully established a predictive model for adverse outcomes in ANOCA patients using clinically accessible variables, which could serve as a valuable tool to risk-stratify patients and customize their management and treatment strategies.

Key word

angina, coronary artery disease, MINOCA, prognosis, nomogram.

Backgrounds

Chest pain is a common symptom among patients seeking medical services, often raising concerns about potentially life-threatening conditions such as coronary artery disease (CAD) [1,2]. Timely and accurate diagnostic assessments, including electrocardiography, coronary computed tomography angiography, and coronary angiography, are frequently recommended for individuals presenting with chest pain to rule out severe conditions such as myocardial infarction (MI) [3,4]. However, in the cohort of patients undergoing diagnostic workup, approximately half exhibit nonobstructive coronary arteries (stenosis less than 50%)[5,6], a condition known as angina with nonobstructive coronary arteries (ANOCA) [7].

ANOCA patients often seek medical care due to symptoms and undergo repetitive invasive examinations, leading to significant healthcare resource utilization and imposing individual burdens and additional risks [8–10]. In a randomized controlled trial involving over 10,000 patients suspected of CAD with intermediate pretest likelihood, only approximately 12% of them yielded a positive result in the final coronary artery functional tests [11]. Patients with a low pretest probability exhibit an exceedingly low positivity rate in diagnostic workup and experience fewer adverse outcomes [12]. Therefore, clinical guidelines recommend delaying diagnostic testing for patients at low risk for CAD[13,14]. However, patients without obstructive coronary arteries confirmed by coronary angiography (CAG) or coronary computed tomography angiography (CCTA) have been observed to experience more adverse outcomes compared to the general population[15–17]. Identifying high-risk patients remains a challenge.

There is limited research on predicting adverse outcomes in ANOCA patients confirmed through CAG or CCTA. Some studies have validated the utility of specific pretest indicators, such as age, sex, and traditional cardiovascular disease risk factors(e.g., hypertension), to identify low-risk ANOCA patients [18]. However, several investigations have shown that specific blood biomarkers, including high-sensitivity troponin and lower HDL-C levels, operate as independent predictive factors for poor prognosis in ANOCA patients, adding prognostic value[19]. To date, comprehensive studies that screen noninvasive indicators and develop a prognostic model are lacking, and most previous studies are reliant on data derived from the Women's Ischemia Syndrome Evaluation (WISE) study[19–21],

which exclusively includes female participants. One study also used WISE data to validate the effectiveness of some risk scores originally designed for other populations, such as the ASCVD score, in predicting adverse outcomes in ANOCA patients, but the results showed suboptimal performance [22]. Therefore, it is necessary to develop a predictive model based on non-invasive indicators to forecast adverse outcomes in ANOCA patients of both sexes. This study aims to bridge this gap to optimize clinical decision-making and patient management.

Method

Study Population

This is a retrospective cohort study that consecutively enrolled patients who presented with suspected symptoms of CAD and underwent coronary angiography at the Department of Cardiology or Emergency Department of the Second Hospital of Tianjin Medical University between January 2019 and June 2023. The Second Hospital of Tianjin Medical University is a cardiac center serving the northern Chinese city of Tianjin and its surrounding regions. This study adheres to the principles outlined in the TRIPOD statement [23].

Patients meeting the following criteria were excluded from the study: (1) patients with acute coronary syndrome or obstructive coronary arteries (defined as a luminal stenosis of ≥50% in a major epicardial coronary artery); (2) patients with a prior diagnosis of CAD, history of percutaneous coronary

intervention (PCI), or coronary artery bypass grafting (CABG); (3) individuals with severe liver or kidney dysfunction, malignancies, or other conditions significantly affecting life expectancy; (4) those with substantial missing baseline data; and (5) patients lost to follow-up. This study received approval from the Ethics Committee of the Second Hospital of Tianjin Medical University, and the requirement for written informed consent from patients was waived.

Clinical Data Collection

Patient data were retrospectively obtained from electronic medical records, including demographic information, medical history, vital sign data, laboratory parameters, echocardiographic data, coronary angiography findings and other relevant details.

Follow-Up and Endpoints

Trained follow-up team members conducted regular patient follow-up after discharge at 30 days, 3 months, 6 months, and annually thereafter. Follow-up was performed using the hospital information system, telephone, or email. The follow-up data for this study were collected up to August 1, 2023.

The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or coronary-artery bypass grafting (CABG) during follow-up. The secondary endpoint was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat

PCI, and CABG during follow-up.

Statistical Analysis

For the small amount of missing data in smoking and alcohol consumption history, multiple imputation was performed using the MICE package (Multiple Imputation by Chained Equations package). To establish a reliable model, the entire study cohort was randomly stratified into two subsets, a training set and a validation set, with a ratio of 0.75 to 0.25, respectively. The training set was used to generate the predictive model, while the validation set was utilized for model internal validation.

Categorical variables were described as frequencies and percentages, with group differences assessed using the chi-square test or Fisher's exact test as applicable. Continuous variables were expressed as either the mean ± standard deviation (SD) or median [interquartile range, IQR], and group comparisons were conducted using the t test or Kruskal–Wallis test as appropriate. The variables selected through LASSO regression were incorporated into the Cox proportional hazards regression model, and a nomogram was generated based on the Cox regression analysis model. The discriminative ability of the predictive model was evaluated using AUC. The model's calibration was assessed through the calibration curve. Additionally, decision curve analysis was employed to evaluate the clinical utility of the nomogram.

The total score for each patient was calculated based on the nomogram, and the study population was

stratified into high-risk and low-risk groups according to the score corresponding to the 3-year 95% event-free survival probability. Event-free survival for the high- and low-risk groups in the training and validation sets was estimated by Kaplan–Meier method and compared with the log-rank test. All statistical analyses were performed with R software version 4.3.1 (R Foundation for Statistical Computing). All statistical tests were two- tailed, with a significance level set at $P<0.05$.

Result

Study Population and Patient Characteristics

Out of a consecutive cohort of 17,816 patients who underwent coronary angiography for suspected coronary artery disease, 9,883 individuals with significant coronary artery stenosis and 1,816 patients with a documented history of coronary heart disease were excluded. An additional 131 individuals were excluded due to missing baseline or follow-up data, and 52 patients with severe conditions such as malignant tumors were also excluded. of the final analysis included 5,934 patients with negative coronary angiography results (**Figure 1**).

The mean age of the overall cohort was 43.6 ± 10.8 years, with 58.3% being female, and the median follow-up time was 631 [270, 972] days. Detailed baseline data are provided in **Supplementary Table 1**. During the follow-up period, 145 (2.44%) patients had primary endpoint events, 82 (1.38%) had MACE, 106 (1.79%) had all-cause death, 33 (0.56%) had MI, and 11 (0.19%) had a stroke. The

Kaplan-Meier method was employed to estimate the survival without various adverse events for the total study population (**Supplementary Figure 1**).

Nomogram built based on LASSO-COX regression

The entire cohort was randomly divided into a training cohort consisting of 4,452 patients and a validation cohort comprising 1,482 patients. There were no statistically significant differences in the collected variables between these two groups (**Supplementary Table 1**). LASSO regression was employed to select variables with the strongest correlation to the primary endpoint. As the regularization parameter (λ) increased, certain coefficients were reduced to zero, effectively eliminating those variables from the model (**Figure 2A**). We used a tenfold cross-validation approach to identify the optimal model. Due to the relatively limited number of cases undergoing primary endpoint events in the validation cohort (145), we employed the one standard error (1-se) rule, resulting in eight selected variables (**Figure 2B**). These variables were incorporated into a Cox proportional hazards regression model, with results presented in **Table 2**. A nomogram was developed based on the Cox regression model, with the regression coefficients of these factors amalgamated into a scoring system, ranging from 0 to 100(**Figure 3**). For example, an 81-year-old male patient with a hemoglobin level of 92 g/L, serum urea of 14.1 mmol/L, serum sodium of 145.6 mmol/L, an ALT/AST ratio of 1.68, NT-proBNP at 272 ng/L, left atrial diameter of 38.83 millimeters, and an LVEF of 62% received a total score of 115. The 1-year, 2-year and 3-year event-free survival rates were 99.5%, 96.2% and 89.0%, respectively.

Table 2. Prediction of event-free survival probability using the Cox proportional hazards regression model based on LASSO regression.

Variable	coefficients	z score	HR	95%CI	p value
Age	0.043	4.167	1.044	0.023, 0.063	<0.001
Hemoglobin	-0.015	-2.871	0.985	-0.026, -0.005	0.004
Urea	0.074	3.947	1.077	0.037, 0.111	<0.001
Serum sodium	-0.074	-5.694	0.929	-0.1, -0.049	<0.001
ALT/AST ratio	0.444	2.439	1.559	0.087, 0.8	0.015
NT-proBNP	0	2.094	1	0, 0	0.036
Left atrial diameter	0.076	5.959	1.079	0.051, 0.8	<0.001
LVEF	-0.022	-2.289	0.979	-0.04, -0.003	0.022

HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase; LVEF, left ventricular ejection fraction.

Discrimination and calibration of the nomogram

The discriminative ability of the model was assessed by plotting receiver operating characteristic curves. In the training set, the AUC for 1-, 2-, and 3-year predictions was 0.82, 0.90, and 0.89, respectively. In the validation set, the corresponding AUC for 1-, 2-, and 3-year predictions were 0.75, 0.77, and 0.78, respectively (**figure 4**).

Figure 5 illustrates calibration plots for the models predicting 1-, 2-, and 3-year survival in both the training and validation datasets. In well-calibrated models, the points closely align with the ideal 45-degree line, indicating that predicted survival closely matches observed survival and demonstrating

good model calibration.

Decision Curve

Decision curve analysis was employed to evaluate the potential improvement in clinical outcomes through nomogram-assisted decision-making for patients. As illustrated in **Figure 6**, the results reveal that across a broad spectrum of threshold probabilities in both the training and testing cohorts, utilizing the nomogram for predicting the 2-year or 3-year event-free survival probability offers a more significant net benefit when compared to strategies of 'treat all' or 'treat none.' These findings underscore the clinical utility of the nomogram.

Risk stratification

Considering that the study population consists of low-risk patients with non-obstructive coronary artery stenosis, the threshold for further risk stratification was set at a higher event-free survival probability, specifically a score of 104 points corresponding to the 95% 3-year event-free survival probability as determined by the nomogram. Individuals scoring below this threshold were categorized as low-risk, while those scoring equal to or above it were classified as high-risk. Kaplan-Meier curves depicting event-free survival were created for the two risk groups in the training and validation sets (**Figure 7**). Furthermore, MACE-event free survival of these groups is shown in **Supplementary Figure 2**. These results consistently demonstrated the model's efficacy in patient risk stratification.

Discussion

This study focused on patients initially suspected of having CAD but who were found to have nonobstructive coronary arteries following coronary angiography. A wide range of variables, including demographic infomation, vital signs, laboratory parameters, and echocardiographic measurements, were meticulously examined. Ultimately, 8 key variables, namely age, hemoglobin levels, serum urea, serum sodium levels, ALT/AST ratio, NT-proBNP levels, left atrial diameter, and LVEF, were identified. The study successfully developed a nomogram to predict the probability of event-free survival for these patients, demonstrating excellent discriminatory and calibration abilities in both the training and validation sets. The utilization of this predictive model in clinical practice empowers healthcare providers to conduct more precise risk stratification, particularly for individuals initially classified as low-risk, thereby improving diagnostic, management, and treatment strategies and ultimately enhancing patient outcomes.

In clinical practice, a substantial number of patients with potential cardiac issues, such as chest pain, actively seek medical attention in both outpatient and emergency department settings. In the United Kingdom, for instance, approximately 1-2% of adults consult primary care facilities when experiencing chest pain for the first time [15]. Similarly, millions of individuals in the United States undergo stress tests in outpatient clinics each year for undiagnosed heart conditions [24]. However, research has

consistently shown that following diagnostic assessments like coronary angiography, approximately 50% of patients do not exhibit obstructive coronary artery stenosis [5,16,25,26]. Traditionally, such patients were often considered to have a favorable prognosis and no significant cardiac conditions , potentially resulting in the omission of further diagnostic measures and therapeutic interventions [27–29]. However, recent research has indicated that these patients face a significantly elevated risk of adverse outcomes compared to the general population. The WISE study revealed that at over a 10-year follow-up, patients without obstructive coronary stenosis on coronary angiography had rates of cardiovascular death and MI of 6.7% and 12.8%, respectively, underscoring the heightened risk among female ANOCA patients [21,30,31]. Other studies have also demonstrated that ANOCA patients, regardless of their gender, face an increased risk of experiencing CAD-related outcomes compared to the general population[16,26,32].

Our findings from this study indicate that ANOCA patients tend to be younger, with an average age of 43.6 years, and a higher proportion of them are female (58.3%) [7]. During a median follow-up period of 2 years, the rates of all-cause death, MI, and stroke were 1.79%, 0.56%, and 0.19%, respectively. These findings align with a previous study reporting 1-year MI rates ranging from 0.11% to 0.59% and 1-year mortality rates ranging from 1.38% to 2.3% [26]. Our research further supports the characterization of ANOCA patients and provides additional evidence of their elevated risk for adverse outcomes across diverse populations.

While clinical guidelines suggest risk stratification of chest pain patients and deferring testing for those

with a low likelihood of CAD, this strategy may inadvertently exclude high-risk ANOCA patients who require further assessment and appropriate therapeutic interventions [13,14]. As highlighted in a recent review, a significant proportion of ANOCA patients (ranging from 75% to 90%) exhibit various underlying causes, such as coronary microvascular dysfunction (CMD), microvascular spasm, endothelial dysfunction, epicardial coronary spasm, and/or myocardial bridging [7,33], emphasizing the critical importance of identifying high-risk ANOCA patients to optimize their further management.

Current research on factors related to adverse outcomes in the ANOCA population is limited. One study attempted to develop a risk tool for chest pain patients with normal coronary arteries to predict favorable outcomes. This tool comprised 10 variables, including age, gender, and the presence of conditions like hypertension, diabetes, or dyslipidemia. However, it is important to note that this study solely relied solely on pretest clinical data and accessed coronary arteries through coronary CTA [18]. In contrast, our predictive model incorporated pre-test indicators, including demographic variables and medical history, with age being one of the key factors. Age is a variable included in many traditional CAD prediction models because it is easily obtainable and reflects the aging of the entire cardiovascular system, including increased arterial stiffness and decreased vascular endothelial function [22,34].

Previous studies have also indicated that several blood biomarkers are associated with unfavorable outcomes in ANOCA patients, including lower levels of HDL-C, elevated levels of soluble urokinase-type plasminogen activator receptor, and high-sensitivity troponin [19,20]. However, none of these

studies conducted comprehensive screening of clinical variables or developed a predictive model. After a thorough screening of blood biomarkers, our predictive model incorporated hemoglobin, serum urea, serum sodium and NT-proBNP, which are rarely reported to be associated with adverse outcomes in ANOCA patients. Anemia, for example, is a common pathological condition involved in the occurrence and development of CAD and heart failure through various mechanisms [35]. It significantly increases the risk of developing CAD and heart failure and is associated with adverse outcomes in these patients [36,37]. Serum urea reflects renal function, which is a crucial factor influencing the cardiovascular system [38]. Previous research has shown that an elevated serum urea levels increase the risk of CAD and serve as a predictive factors for adverse outcomes in CAD and heart failure patients [39,40]. The role of serum sodium in cardiovascular disease is still not fully understood, but several studies have indicated that even mild reductions in serum sodium, even within the normal range, are associated with higher all-cause mortality and cardiovascular mortality in elderly individuals or the general population [41–44]. The underlying mechanisms behind this association require further research. NT-proBNP is a widely recognized marker for heart failure and exhibits strong predictive capabilities for the prognosis of heart failure patients [45]. Previous studies have also demonstrated its ability to predict cardiovascular events and mortality even in community-dwelling or elderly populations without heart failure [46–49].

Our predictive model also considered echocardiographic parameters. Echocardiography is a noninvasive, easily performed, and cost-effective imaging technique that provides comprehensive insights into cardiac structure and function. In our model, left atrial diameter and LVEF were included.

Left atrial enlargement is closely associated with conditions like atrial fibrillation and heart failure, and factors such as hypertension and mitral valve diseases can also lead to left atrial enlargement. It is commonly regarded as a biomarker for adverse cardiovascular outcomes [50–53]. The LVEF serves as one of the diagnostic and classificatory criteria for heart failure, with the latter often signifying the advanced stage of diverse cardiac ailments and indicates an unfavorable prognosis [54,55].

Strengths and limitations

This study has several limitations. First, it is a retrospective study conducted at a single medical center, which may introduce some potential biases. Second, the study population consisted entirely of individuals from northern China, so caution should be exercised when generalizing the findings of this study to other populations. Third, due to the limitations of retrospective research, we were unable to further subdivide nonobstructive coronary stenosis into "normal coronary" (without significant coronary atherosclerosis) and "nonobstructive CAD" (stenosis <50%), although these two groups may have similar subsequent management. Finally, the predictive model lacks validation in an external population, but internal validation was performed, and it demonstrated good discrimination and calibration.

Conclusion

In summary, we conducted a comprehensive evaluation of clinically accessible variables and

successfully developed a predictive model for assessing adverse outcomes in patients with suspected CAD who do not exhibit obstructive coronary artery stenosis. This nomogram equips clinicians with a valuable tool for risk stratification in ANOCA patients, allowing for optimized management and treatment strategies aimed at improving patient outcomes.

List of abbreviations

ANOCA, angina with nonobstructive coronary arteries

ACU, areas under the curve

ALT, alanine transaminase

AST, aspartate transaminase

LVEF, left ventricular ejection fraction

CAD, coronary artery disease

MI, myocardial infarction

CAG, coronary angiography

CCTA, coronary computed tomography angiography

HDL-C, high-density lipoprotein cholesterol

PCI, percutaneous coronary intervention

CABG, coronary-artery bypass grafting

MACE, major adverse cardiovascular events

Sources of Funding

This study was supported by the Key Project of Tianjin Natural Science Foundation (Grant Number: 21JCZDJC01080), Academic Backbone of "Clinical Talent Training and Climbing Plan" of Tianjin Medical University and Sponsored by Tianjin Health Research Project.

Availability of data and materials

The original data supporting the findings of this study can be obtained from the corresponding author upon request.

Author contributions

ZL and CKY conceived and designed the protocol; ZL, XZK, HST, ZYK, and GTS collected the data; ZL analyzed the data; ZL wrote the manuscript; CKY, RHW, LT, ZJK, XZK, HST, ZYK, GTS and WX critically revised the manuscript. All authors contributed to the article and approved the submitted version.

Disclosures

The authors do not have any associations that are pertinent to the subject matter of this paper to disclose.

References

1 Hoorweg BB, Willemsen RT, Cleef LE, *et al.* Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. *Heart Br Card Soc*. 2017;103:1727–32. doi: 10.1136/heartjnl-2016-310905

2 Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145:e153–639. doi: 10.1161/CIR.0000000000001052

3 Virani SS, Newby LK, Arnold SV, *et al.* 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023;148:e9–119. doi: 10.1161/CIR.0000000000001168

4 Fihn SD, Gardin JM, Abrams J, *et al.* 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart

Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83

5 Patel MR, Peterson ED, Dai D, *et al.* Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010;362:886–95. doi: 10.1056/NEJMoa0907272

6 Rahman H, Corcoran D, Aetesam-Ur-Rahman M, *et al.* Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. *Heart Br Card Soc*. 2019;105:1536–42. doi: 10.1136/heartjnl-2019-315042

7 Samuels BA, Shah SM, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023;82:1245–63. doi: 10.1016/j.jacc.2023.06.043

8 Shaw LJ, Merz CNB, Pepine CJ, *et al.* The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. *Circulation*. 2006;114:894–904. doi: 10.1161/CIRCULATIONAHA.105.609990

9 Gulati M, Khan N, George M, *et al.* Ischemia with no obstructive coronary artery disease (INOCA): A patient self-report quality of life survey from INOCA international. *Int J Cardiol*. 2023;371:28–39. doi: 10.1016/j.ijcard.2022.09.047

10 Takahashi T, Samuels BA, Li W, *et al.* Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols. *J Am Coll Cardiol*. 2022;79:2367–78. doi: 10.1016/j.jacc.2022.03.385

11 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516

12 Udelson JE, Kelsey MD, Nanna MG, *et al.* Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial. *JAMA Cardiol*. Published Online First: 23 August 2023. doi: 10.1001/jamacardio.2023.2614

13 Gulati M, Levy PD, Mukherjee D, *et al.* 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;144:e368–454. doi: 10.1161/CIR.0000000000001029

14 Knuuti J, Wijns W, Saraste A, *et al.* 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77. doi: 10.1093/eurheartj/ehz425

15 Jordan KP, Timmis A, Croft P, *et al.* Prognosis of undiagnosed chest pain: linked electronic health record cohort study. *BMJ*. 2017;357:j1194. doi: 10.1136/bmj.j1194

16 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J*. 2012;33:734–44. doi: 10.1093/eurheartj/ehr331

17 Gulati M, Cooper-DeHoff RM, McClure C, *et al.* Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009;169:843–50. doi: 10.1001/archinternmed.2009.50

18 Fordyce CB, Douglas PS, Roberts RS, *et al.* Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2017;2:400–8. doi: 10.1001/jamacardio.2016.5501

19 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515

20 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3

21 Sharaf B, Wood T, Shaw L, *et al.* Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. *Am Heart J*. 2013;166:134–41. doi: 10.1016/j.ahj.2013.04.002

22 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome Evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi: 10.1161/JAHA.119.013234

23 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*. 2015;350:g7594. doi: 10.1136/bmj.g7594

24 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516

25 Bairey Merz CN, Pepine CJ, Walsh MN, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. *Circulation*. 2017;135:1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534

26 Maddox TM, Stanislawski MA, Grunwald GK, *et al.* Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA*. 2014;312:1754–63. doi: 10.1001/jama.2014.14681

27 Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. *JAMA*. 2005;293:477–84. doi: 10.1001/jama.293.4.477

28 Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. *J Am Coll Cardiol*. 1995;25:1013–8. doi: 10.1016/0735-1097(94)00519-v

29 Kaski JC, Rosano GM, Collins P, *et al.* Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. *J Am Coll Cardiol*. 1995;25:807–14. doi: 10.1016/0735-1097(94)00507-M

30 Sharaf BL, Pepine CJ, Kerensky RA, *et al.* Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–41; A3. doi: 10.1016/s0002-9149(01)01424-2

31 Kenkre TS, Malhotra P, Johnson BD, *et al.* Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). *Circ Cardiovasc Qual Outcomes*. 2017;10:e003863. doi: 10.1161/CIRCOUTCOMES.116.003863

32 Sedlak TL, Lee M, Izadnegahdar M, *et al.* Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. *Am Heart J*. 2013;166:38–44. doi: 10.1016/j.ahj.2013.03.015

33 Smilowitz NR, Prasad M, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023;82:1264–79. doi: 10.1016/j.jacc.2023.06.044

34 Moreau P, d'Uscio LV, Lüscher TF. Structure and reactivity of small arteries in aging. *Cardiovasc Res*. 1998;37:247–53. doi: 10.1016/s0008-6363(97)00225-3

35 Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. *Coron Artery Dis*. 2018;29:161–7. doi: 10.1097/MCA.0000000000000598

36 Gan T, Hu J, Liu W, *et al.* Causal Association Between Anemia and Cardiovascular Disease: A 2-Sample Bidirectional Mendelian Randomization Study. *J Am Heart Assoc*. 2023;12:e029689. doi: 10.1161/JAHA.123.029689

37 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. *Circulation*. 2003;107:223–5. doi: 10.1161/01.cir.0000052622.51963.fc

38 Herzog CA, Asinger RW, Berger AK, *et al.* Cardiovascular disease in chronic kidney disease. A

clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2011;80:572–86. doi: 10.1038/ki.2011.223

39 Liu F, Ma G, Tong C, *et al.* Elevated blood urea nitrogen-to-creatinine ratio increased the risk of Coronary Artery Disease in patients living with type 2 diabetes mellitus. *BMC Endocr Disord*. 2022;22:50. doi: 10.1186/s12902-022-00954-3

40 Kirtane AJ, Leder DM, Waikar SS, *et al.* Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol*. 2005;45:1781–6. doi: 10.1016/j.jacc.2005.02.068

41 He X, Liu C, Chen Y, *et al.* Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. *Can J Cardiol*. 2018;34:999–1003. doi: 10.1016/j.cjca.2018.03.013

42 Wannamethee SG, Shaper AG, Lennon L, *et al.* Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: A population-based cohort study. *Nutr Metab Cardiovasc Dis NMCD*. 2016;26:12–9. doi: 10.1016/j.numecd.2015.07.008

43 Ahn SY, Park YS, Lee SW, *et al.* Association Between Small Decrease in Serum Sodium Concentration within the Normal Range and All-Cause and Cardiovascular Mortality in Elderly Adults over 5 Years. *J Am Geriatr Soc*. 2016;64:510–7. doi: 10.1111/jgs.13937

44 Sajadieh A, Binici Z, Mouridsen MR, *et al.* Mild hyponatremia carries a poor prognosis in community subjects. *Am J Med*. 2009;122:679–86. doi: 10.1016/j.amjmed.2008.11.033

45 Doust JA, Pietrzak E, Dobson A, *et al.* How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ*. 2005;330:625. doi: 10.1136/bmj.330.7492.625

46 McKie PM, Rodeheffer RJ, Cataliotti A, *et al.* Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertens Dallas Tex 1979*. 2006;47:874–80. doi: 10.1161/01.HYP.0000216794.24161.8c

47 Wang TJ, Larson MG, Levy D, *et al.* Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–63. doi: 10.1056/NEJMoa031994

48 Rosenberg J, Schou M, Gustafsson F, *et al.* Prognostic threshold levels of NT-proBNP testing in primary care. *Eur Heart J*. 2009;30:66–73. doi: 10.1093/eurheartj/ehn525

49 Kistorp C, Raymond I, Pedersen F, *et al.* N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA*. 2005;293:1609–16. doi: 10.1001/jama.293.13.1609

50 Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and

Clinical Significance. *JACC Cardiovasc Imaging*. 2017;10:65–77. doi: 10.1016/j.jcmg.2016.11.003

51 Krahn AD, Manfreda J, Tate RB, *et al.* The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med*. 1995;98:476–84. doi: 10.1016/S0002-9343(99)80348-9

52 Marsan NA, Maffessanti F, Tamborini G, *et al.* Left atrial reverse remodeling and functional improvement after mitral valve repair in degenerative mitral regurgitation: a real-time 3-dimensional echocardiography study. *Am Heart J*. 2011;161:314–21. doi: 10.1016/j.ahj.2010.10.029

53 Lloyd-Jones DM, Wang TJ, Leip EP, *et al.* Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004;110:1042–6. doi: 10.1161/01.CIR.0000140263.20897.42

54 Bozkurt B, Coats AJS, Tsutsui H, *et al.* Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail*. 2021;23:352–80. doi: 10.1002/ejhf.2115

55 Heidenreich PA, Bozkurt B, Aguilar D, *et al.* 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e895–1032. doi: 10.1161/CIR.0000000000001063

Figure and table

Figure 1. Flowchart of study participation. CAD, coronary artery disease.



Figure 2. Variable Selection Based on LASSO Regression. (A) Variation Characteristics of Variable Coefficients; (B) Selection Process of Optimal λ Value in LASSO Regression Model Using Cross-

542 Validation.



543

544

545 **Figure 3. Nomogram for predicting the probability of 1-, 2-, and 3-year event-free survival of**

546 **ANOCA patients as assessed by coronary angiography.** ALT, alanine transaminase; AST, aspartate

transaminase; LVEF, left ventricular ejection fraction.



Figure 4. Receiver operating characteristic curve for the 1-, 2-, and 3-year primary endpoints of the nomogram in the training set (A) and validation set (B). AUC, area under receiver operating characteristic curve.



Figure 5. Calibration plot of predicted 1-, 2-, and 3-year event-free survival based on the nomogram in the training set and validation set. (A–C) Training set; (D–F) Validation set.



Figure 6. Decision curve analysis of the nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the threshold probability, and the y-axis measures the net benefit. The left-slanting straight line shows the net benefit of treating all patients. The bottom horizontal gray line represents the net benefit of not treating any patients. The curve in the middle represents the nomogram.



Figure 7. Kaplan-Meier curves for 1-year, 2-year, and 3-year event-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



Supplementary Table 1. Clinical data of the total population, training set and validation set.

Supplementary Figure 1. Event-free survival probability of different adverse events in the total population.

Supplementary Figure 2. Kaplan-Meier curves for 1-year, 2-year, and 3-year MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



A



B





A



B



A



D



B



E



C



F



A



B



A



Number at risk

Risk					
Low	3946	2875	1906	927	66
High	506	353	189	71	10

Time (Days): 0, 400, 800, 1200, 1600

B



Number at risk

Risk					
Low	1336	993	648	325	34
High	146	92	51	20	0

Time (Days): 0, 400, 800, 1200, 1600

Supplement

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
Female, n (%)	3462 (58.3%)	2609 (58.6%)	853 (57.6%)	0.499
Age, years	43.6 (10.8)	43.7 (10.9)	43.5 (10.6)	0.563
Smoking, n (%)	1509 (25.4%)	1126 (25.3%)	383 (25.8%)	0.698
Drinking, n (%)	1883 (31.7%)	1415 (31.8%)	468 (31.6%)	0.909
Hypertension, n (%)	3698 (62.3%)	2802 (62.9%)	896 (60.5%)	0.094
Diabetes mellitus, n (%)	1123 (18.9%)	846 (19.0%)	277 (18.7%)	0.820
Diabetic complications, n (%)	19 (0.32%)	13 (0.29%)	6 (0.40%)	0.595
Dyslipidemia, n (%)	582 (9.81%)	423 (9.50%)	159 (10.7%)	0.185
CKD, n (%)	202 (3.40%)	151 (3.39%)	51 (3.44%)	0.993
SBP, mmHg	136 (19.8)	136 (19.9)	136 (19.7)	0.340
DBP, mmHg	81.9 (12.3)	81.9 (12.4)	81.8 (11.9)	0.757
Heart rate, beats/min	73.8 (15.2)	73.8 (13.9)	73.9 (18.5)	0.798
WBC, 10^9/L	6.67 (2.03)	6.68 (2.01)	6.67 (2.11)	0.969
Hemoglobin, g/L	136 (16.6)	136 (16.6)	136 (16.4)	0.881
Urea, mmol/L	6.09 (2.68)	6.09 (2.72)	6.08 (2.57)	0.831
Serum creatinine, μmol/L	65.9 [55.7; 79.8]	66.2 [55.7; 79.7]	65.4 [55.5; 80.0]	0.748
Uric acid, μmol/L	335 (100)	335 (101)	335 (99.0)	0.889
Serum sodium, mmol/L	142 (3.51)	142 (3.32)	142 (4.01)	0.829
Serum potassium, mmol/L	4.12 (0.56)	4.12 (0.47)	4.13 (0.76)	0.649
Serum chloride, mmol/L	106 (3.37)	106 (3.42)	106 (3.21)	0.515
Anion gap, mmol/L	14.0 (2.40)	13.9 (2.40)	14.0 (2.42)	0.844

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
Total protein, g/L	68.2 (6.41)	68.2 (6.37)	68.2 (6.54)	0.968
Albumin, g/L	42.4 (3.88)	42.4 (3.87)	42.3 (3.91)	0.406
Globulin, g/L	25.9 (4.19)	25.8 (4.16)	25.9 (4.30)	0.353
ALT, U/L	17.7 [13.0; 24.7]	17.8 [13.1; 24.8]	17.6 [12.6; 24.5]	0.169
AST, U/L	17.7 [14.6; 21.6]	17.8 [14.6; 21.6]	17.5 [14.6; 21.5]	0.341
ALT/AST ratio	1.06 (0.41)	1.05 (0.41)	1.07 (0.42)	0.157
Total bilirubin, μmol/L	13.6 (6.67)	13.6 (6.81)	13.4 (6.23)	0.257
Indirect Bilirubin, μmol/L	9.63 (4.69)	9.67 (4.75)	9.51 (4.53)	0.242
Direct Bilirubin, μmol/L	3.40 [2.30; 4.60]	3.40 [2.30; 4.60]	3.40 [2.40; 4.60]	0.611
Alkaline phosphatase, U/L	76.5 (23.6)	76.5 (23.6)	76.6 (23.7)	0.820
Total cholesterol, mmol/L	4.75 (1.12)	4.75 (1.13)	4.74 (1.08)	0.919
Triglycerides, mmol/L	1.63 (1.11)	1.62 (1.11)	1.65 (1.10)	0.485
HDL-C, mmol/L	1.22 (0.31)	1.22 (0.32)	1.20 (0.30)	0.083
LDL-C, mmol/L	2.97 (0.88)	2.97 (0.88)	2.98 (0.87)	0.498
VLDL-C, mmol/L	0.56 (0.37)	0.56 (0.39)	0.56 (0.30)	0.627
Troponin I, ng/ml	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.536
NT-proBNP, ng/L	83.7 [35.1; 266]	83.0 [34.3; 265]	86.7 [38.0; 269]	0.415
CKMB, U/L	12.1 [9.30; 14.7]	12.0 [9.24; 14.7]	12.3 [9.30; 14.7]	0.529
D-Dimer, μg/L	276 [2.34; 434]	274 [1.78; 427]	282 [4.65; 457]	0.110
Glucose, mmol/L	6.81 (2.48)	6.82 (2.45)	6.78 (2.56)	0.579
Left atrial diameter, mm	38.7 (5.24)	38.7 (5.28)	38.6 (5.11)	0.331

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
LVEDD, mm	47.4 (4.46)	47.4 (4.51)	47.3 (4.28)	0.373
LVESD, mm	26.9 (5.62)	26.9 (5.65)	27.0 (5.52)	0.737
RVEDD, mm	20.8 (3.37)	20.7 (3.61)	20.8 (2.53)	0.623
LVEF, %	61.7 (6.75)	61.7 (6.77)	61.6 (6.70)	0.486
Event-free survival time, days	635 (403)	633 (402)	641 (406)	0.512
Death, n (%)	106 (1.79%)	78 (1.75%)	28 (1.89%)	0.816
MI endpoint, n (%)	33 (0.56%)	21 (0.47%)	12 (0.81%)	0.189
Stroke endpoint, n (%)	11 (0.19%)	6 (0.13%)	5 (0.34%)	0.156
MACE, n (%)	82 (1.38%)	64 (1.44%)	18 (1.21%)	0.611
Primary endpoint, n (%)	145 (2.44%)	105 (2.36%)	40 (2.70%)	0.523

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; CKMB, creatine kinase-MB; LVEDD, left ventricular-end-diastolic diameter; LVESD, left ventricular-end-systolic diameter; RVEDD, right ventricular-end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACE, major adverse cardiovascular events.

Supplementary Figure 1. Event-free survival probability of different adverse events in the total population



Supplementary Figure 2. Kaplan-Meier curves for 1-year, 2-year, and 3-year MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



BMJ Open

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2024-092614.R1
Article Type:	Original research
Date Submitted by the Author:	06-Mar-2025
Complete List of Authors:	Zhu, Lei; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Xue, Zheng-Kai; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Wu, Xue; University of California San Francisco, Institute for Global Health Sciences Zhang, JingKun; University of California San Francisco, Cardiovascular Research Institute Hu, Su-Tao; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Zhang, Yu-Kun; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Gu, Tian-Shu; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Liu, Tong; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Rha, Seung-Woon; Korea University Guro Hospital, Cardiovascular Center Chen, Kang-Yin; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Angina Pectoris, Coronary heart disease < CARDIOLOGY, Prognosis

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

Authors: Lei Zhu[1], Zheng-Kai Xue[1], Xue Wu[2], Jing-Kun Zhang[3], Su-Tao Hu [1], Yu-Kun Zhang[1], Tian-Shu Gu[1], Tong Liu[1], Seung-Woon Rha[4], Kang-Yin Chen[1*]

Affiliations: [1] Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China

[2] Institute for Global Health Sciences, University of California, San Francisco, CA, USA

[3] Cardiovascular Research Institute, University of California San Francisco, CA, USA

[4] Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.

***Corresponding author:** Kang-Yin Chen, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China (chenkangyin@vip.126.com)

Word count: 3074

Abstract

Objectives

To develop and validate a risk prediction model for adverse outcomes in patients with angina with nonobstructive coronary arteries (ANOCA) confirmed by invasive coronary angiography.

Design

Retrospective cohort study.

Setting

A tertiary cardiovascular care center in East Asia.

Participants

From 17,816 consecutive patients undergoing coronary angiography for suspected coronary artery disease, 5,934 met ANOCA criteria after rigorous exclusion: (1) significant stenosis (≥50% luminal narrowing), (2) established coronary artery disease history, (3) incomplete baseline/follow-up data, (4) non-cardiovascular life-limiting conditions.

primary and secondary outcome measures

The primary outcome was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or coronary-artery bypass grafting (CABG). The secondary outcome was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG.

Results

The derivation cohort (n=4,452) and validation cohort (n=1,482) demonstrated comparable baseline

characteristics. The nomogram incorporated eight prognosticators: age, hemoglobin, serum urea, serum sodium, ALT/AST ratio, NT-proBNP, left atrial diameter, and LVEF. The prediction model showed robust discrimination for primary endpoint (derivation AUC: 0.82 [1-year], 0.90 [2-year], 0.89 [3-year]; validation AUC: 0.75, 0.77, 0.78). Calibration plots revealed close alignment between predicted and actual event-free survival probabilities in both cohorts. Risk stratification identified two distinct prognostic groups with significant survival differences (log-rank $p < 0.0001$).

Conclusions

This predictive model integrates routinely available clinical parameters to accurately stratify mortality and cardiovascular risk in ANOCA patients, providing a potential valuable decision-support tool for personalized therapeutic strategies.

Strengths and limitations of this study

- This study utilized a large sample size (n=5934) with rigorous internal validation through training and testing cohorts.
- Leveraged LASSO-penalized Cox regression with 10-fold cross-validation to optimize model generalizability.
- The nomogram integrates routinely available clinical variables, enhancing clinical applicability.
- Limitations include the retrospective design, which may introduce selection bias.
- Data were derived from a single center, potentially limiting generalizability.

Key word

Angina, coronary artery disease, MINOCA, prognosis, nomogram.

Backgrounds

Chest pain is a common symptom among patients seeking medical services, often raising concerns about potentially life-threatening conditions such as coronary artery disease (CAD) [1,2]. Timely and accurate diagnostic assessments, including electrocardiography, coronary computed tomography angiography, and coronary angiography, are frequently recommended for individuals presenting with chest pain to rule out severe conditions such as myocardial infarction (MI) [3,4]. However, in the cohort of patients undergoing diagnostic workup, approximately half exhibit nonobstructive coronary arteries (stenosis less than 50%)[5,6], a condition known as angina with nonobstructive coronary arteries (ANOCA) [7].

ANOCA patients often seek medical care due to symptoms and undergo repetitive invasive examinations, leading to significant healthcare resource utilization and imposing individual burdens and additional risks [8–10]. In a randomized controlled trial involving over 10,000 patients suspected of CAD with intermediate pretest likelihood, only approximately 12% of them yielded a positive result in the final coronary artery functional tests [11]. Patients with a low pretest probability exhibit an exceedingly low positivity rate in diagnostic workup and experience fewer adverse outcomes [12]. Therefore, clinical guidelines recommend delaying diagnostic testing for patients at low risk for CAD[13,14]. However, patients without obstructive coronary arteries confirmed by coronary angiography (CAG) or coronary computed tomography angiography (CCTA) have been observed to experience more adverse outcomes compared to the general population[15–17]. Identifying high-risk individuals in ANOCA patients remains a challenge.

There is limited research on predicting adverse outcomes in ANOCA patients confirmed through CAG or CCTA. Some studies have validated the utility of specific pretest indicators, such as age, sex, and traditional cardiovascular disease risk factors(e.g., hypertension), to identify low-risk ANOCA patients [18]. However, several investigations have shown that specific blood biomarkers, including high-sensitivity troponin and lower HDL-C levels, operate as independent predictive factors for poor prognosis in ANOCA patients, adding prognostic value[19]. To date, comprehensive studies that screen noninvasive indicators and develop a prognostic model are lacking, and most previous studies are reliant on data derived from the Women's Ischemia Syndrome Evaluation (WISE) study[19–21], which exclusively includes female participants. One study also used WISE data to validate the effectiveness of some risk scores originally designed for other populations, such as the ASCVD score, in predicting adverse outcomes in ANOCA patients, but the results showed suboptimal performance[22]. Therefore, it is necessary to develop a predictive model based on non-invasive indicators to forecast adverse outcomes in ANOCA patients of both sexes. This study aims to bridge this gap to optimize clinical decision-making and patient management.

Method

Study Population

This is a retrospective cohort study that consecutively enrolled patients who presented with suspected

symptoms of CAD and underwent coronary angiography at the Department of Cardiology or Emergency Department of the Second Hospital of Tianjin Medical University between January 2019 and June 2023. The Second Hospital of Tianjin Medical University is a cardiac center serving the northern Chinese city of Tianjin and its surrounding regions. This study adheres to the principles outlined in the TRIPOD statement [23].

ANOCA patients were defined as angina with nonobstructive epicardial coronary arteries (stenosis <50%), adhering to current expert consensus[7]. Patients meeting the following criteria were excluded from the study: (1) patients with acute coronary syndrome or obstructive coronary arteries (defined as a luminal stenosis of ≥50% in a major epicardial coronary artery[7,24]); (2) patients with a prior diagnosis of CAD, history of percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG); (3) individuals with severe liver or kidney dysfunction, malignancies, or other non-cardiovascular conditions significantly affecting life expectancy; (4) those with substantial missing baseline data; and (5) patients lost to follow-up. This study received approval from the Ethics Committee of the Second Hospital of Tianjin Medical University, with a waiver for written informed consent granted for the retrospective use of fully anonymized clinical data (No. KY2025K008).

Clinical Data Collection

Patient data were retrospectively obtained from electronic medical records, including demographic information, medical history, vital sign data, laboratory parameters, echocardiographic data, coronary

angiography findings and other relevant details.

Follow-Up and Endpoints

A dedicated follow-up team conducted systematic post-discharge surveillance through a standardized protocol, with scheduled assessments at 30 days, 3 months, 6 months, and annually thereafter. Data collection employed a multimodal approach: (1) comprehensive electronic health record review, (2) cross-referencing with regional death registries, (3) and telephone or email interviews. The observational window for this analysis was finalized on August 1, 2023. Two board-certified cardiologists (L.Z. and Z.K.X., each with >5 years clinical experience) independently evaluated all events using standardized diagnostic criteria[25,26]. For discrepancies in event classification, an adjudication committee comprising two senior interventional cardiologists (T.L. and K.Y.C., both with >20 years catheterization laboratory experience) conducted final arbitration through consensus review.

The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or coronary-artery bypass grafting (CABG) during follow-up. The secondary endpoint was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG during follow-up. The composite endpoint was selected based on its established utility in prognostic studies of ANOCA [22,27–29].

Statistical Analysis

For the small amount of missing data in smoking and alcohol consumption history, multiple imputation was performed using the MICE package (Multiple Imputation by Chained Equations package). To establish a reliable model, the entire study cohort was randomly stratified into two subsets, a training set and a validation set, with a ratio of 0.75 to 0.25, respectively. The training set was used to generate the predictive model, while the validation set was utilized for model internal validation.

Categorical variables were described as frequencies and percentages, with group differences assessed using the chi-square test or Fisher's exact test as applicable. Continuous variables were expressed as either the mean ± standard deviation (SD) or median [interquartile range, IQR], and group comparisons were conducted using the t test or Kruskal–Wallis test as appropriate. Variables with VIF ≥5 were excluded prior to LASSO regression to mitigate multicollinearity. The variables selected through LASSO regression were incorporated into the Cox proportional hazards regression model, and a nomogram was generated based on the Cox regression analysis model. The discriminative ability of the predictive model was evaluated using AUC. The model's calibration was assessed through the calibration curve. Additionally, decision curve analysis was employed to evaluate the clinical utility of the nomogram.

The total score for each patient was calculated based on the nomogram, and the study population was stratified into high-risk and low-risk groups according to the score corresponding to the 3-year 95% event-free survival probability. Event-free survival for the high- and low-risk groups in the training

and validation sets was estimated by Kaplan–Meier method and compared with the log-rank test. All statistical analyses were performed with R software version 4.3.1 (R Foundation for Statistical Computing). All statistical tests were two- tailed, with a significance level set at P<0.05.

Patient and public involvement

None.

Result

Study Population and Patient Characteristics

Out of a consecutive cohort of 17,816 patients who underwent coronary angiography for suspected coronary artery disease, 9,883 individuals with significant coronary artery stenosis and 1,816 patients with a documented history of coronary heart disease were excluded. An additional 131 individuals were excluded due to missing baseline or follow-up data, and 52 patients with severe conditions such as malignant tumors were also excluded. of the final analysis included 5,934 patients with negative coronary angiography results (**Figure 1**).

The mean age of the overall cohort was 43.6 ± 10.8 years, with 58.3% being female, and the median follow-up time was 631 [270, 972] days. Detailed baseline data are provided in **Supplementary Table 1**. During the follow-up period, 145 (2.44%) patients had primary endpoint events, 82 (1.38%) had MACE, 106 (1.79%) had all-cause death, 33 (0.56%) had MI, and 11 (0.19%) had a stroke. The

Kaplan-Meier method was employed to estimate the survival without various adverse events for the total study population (**Supplementary Figure 1**).

Nomogram built based on LASSO-COX regression

The entire cohort was randomly divided into a training cohort consisting of 4,452 patients and a validation cohort comprising 1,482 patients. There were no statistically significant differences in the collected variables between these two groups (**Supplementary Table 1**). LASSO regression was employed to select variables with the strongest correlation to the primary endpoint. As the regularization parameter (λ) increased, certain coefficients were reduced to zero, effectively eliminating those variables from the model (**Figure 2A**). We used a tenfold cross-validation approach to identify the optimal model. Due to the relatively limited number of cases undergoing primary endpoint events in the validation cohort (145), we employed the one standard error (1-se) rule, resulting in eight selected variables (**Figure 2B**). These variables were incorporated into a Cox proportional hazards regression model, with results presented in **Table 1**. All models satisfied proportional hazards assumptions (global test p=0.057). A nomogram was developed based on the Cox regression model, with the regression coefficients of these factors amalgamated into a scoring system, ranging from 0 to 100(**Figure 3**). For example, an 81-year-old male patient with a hemoglobin level of 92 g/L, serum urea of 14.1 mmol/L, serum sodium of 145.6 mmol/L, an ALT/AST ratio of 1.68, NT-proBNP at 272 ng/L, left atrial diameter of 38.83 millimeters, and an LVEF of 62% received a total score of 115. The 1-year, 2-year and 3-year event-free survival rates were 99.5%, 96.2% and 89.0%, respectively.

Table 1. Prediction of event-free survival probability using the Cox proportional hazards regression model based on LASSO regression.

Variable	coefficients	z score	HR	95%CI	p value
Age	0.043	4.167	1.044	0.023, 0.063	<0.001
Hemoglobin	-0.015	-2.871	0.985	-0.026, -0.005	0.004
Urea	0.074	3.947	1.077	0.037, 0.111	<0.001
Serum sodium	-0.074	-5.694	0.929	-0.1, -0.049	<0.001
ALT/AST ratio	0.444	2.439	1.559	0.087, 0.8	0.015
NT-proBNP	0	2.094	1	0, 0	0.036
Left atrial diameter	0.076	5.959	1.079	0.051, 0.8	<0.001
LVEF	-0.022	-2.289	0.979	-0.04, -0.003	0.022

HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase; LVEF, left ventricular ejection fraction.

Discrimination and calibration of the nomogram

The discriminative ability of the model was assessed by plotting receiver operating characteristic curves. In the training set, the AUC for 1-, 2-, and 3-year predictions was 0.82, 0.90, and 0.89, respectively. In the validation set, the corresponding AUC for 1-, 2-, and 3-year predictions were 0.75, 0.77, and 0.78, respectively (**figure 4**).

Figure 5 illustrates calibration plots for the models predicting 1-, 2-, and 3-year survival in both the training and validation datasets. In well-calibrated models, the points closely align with the ideal 45-degree line, indicating that predicted survival closely matches observed survival and demonstrating

good model calibration.

Decision Curve

Decision curve analysis was employed to evaluate the potential improvement in clinical outcomes through nomogram-assisted decision-making for patients. As illustrated in **Figure 6**, the results reveal that across a broad spectrum of threshold probabilities in both the training and testing cohorts, utilizing the nomogram for predicting the 2-year or 3-year event-free survival probability offers a more significant net benefit when compared to strategies of 'treat all' or 'treat none.' These findings underscore the clinical utility of the nomogram.

Risk stratification

Considering that the study population consists of low-risk patients with non-obstructive coronary artery stenosis, the threshold for further risk stratification was set at a higher event-free survival probability, specifically a score of 104 points corresponding to the 95% 3-year event-free survival probability as determined by the nomogram. Individuals scoring below this threshold were categorized as low-risk, while those scoring equal to or above it were classified as high-risk. Kaplan-Meier curves depicting event-free survival were created for the two risk groups in the training and validation sets (**Figure 7**). Furthermore, MACE-event free survival of these groups is shown in **Supplementary Figure 2**. These results consistently demonstrated the model's efficacy in patient risk stratification.

Discussion

This study focused on patients initially suspected of having CAD but who were found to have nonobstructive coronary arteries following coronary angiography. A wide range of variables, including demographic information, vital signs, laboratory parameters, and echocardiographic measurements, were meticulously examined. Ultimately, 8 key variables, namely age, hemoglobin levels, serum urea, serum sodium levels, ALT/AST ratio, NT-proBNP levels, left atrial diameter, and LVEF, were identified. The study successfully developed a nomogram to predict the probability of event-free survival for these patients, demonstrating excellent discriminatory and calibration abilities in both the training and validation sets. The utilization of this predictive model in clinical practice empowers healthcare providers to conduct more precise risk stratification, particularly for individuals initially classified as low-risk, thereby improving diagnostic, management, and treatment strategies and ultimately enhancing patient outcomes.

In clinical practice, a substantial number of patients with potential cardiac issues, such as chest pain, actively seek medical attention in both outpatient and emergency department settings. In the United Kingdom, for instance, approximately 1-2% of adults consult primary care facilities when experiencing chest pain for the first time [15]. Similarly, millions of individuals in the United States undergo stress tests in outpatient clinics each year for undiagnosed heart conditions [30]. However, research has

consistently shown that following diagnostic assessments like coronary angiography, approximately 50% of patients do not exhibit obstructive coronary artery stenosis [5,16,24,31]. Traditionally, such patients were often considered to have a favorable prognosis and no significant cardiac conditions , potentially resulting in the omission of further diagnostic measures and therapeutic interventions [32–34]. However, recent research has indicated that these patients face a significantly elevated risk of adverse outcomes compared to the general population. The WISE study revealed that at over a 10-year follow-up, patients without obstructive coronary stenosis on coronary angiography had rates of cardiovascular death and MI of 6.7% and 12.8%, respectively, underscoring the heightened risk among female ANOCA patients [21,35,36]. Other studies have also demonstrated that ANOCA patients, regardless of their gender, face an increased risk of experiencing CAD-related outcomes compared to the general population[16,31,37].

Our findings from this study indicate that ANOCA patients tend to be younger, with an average age of 43.6 years, and a higher proportion of them are female (58.3%) [7]. During a median follow-up period of 2 years, the rates of all-cause death, MI, and stroke were 1.79%, 0.56%, and 0.19%, respectively. These findings align with a previous study reporting 1-year MI rates ranging from 0.11% to 0.59% and 1-year mortality rates ranging from 1.38% to 2.3% [31]. Our research further supports the characterization of ANOCA patients and provides additional evidence of their elevated risk for adverse outcomes across diverse populations.

While clinical guidelines suggest risk stratification of chest pain patients and deferring testing for those

with a low likelihood of CAD, this strategy may inadvertently exclude high-risk ANOCA patients who require further assessment and appropriate therapeutic interventions [13,14]. As highlighted in a recent review, a significant proportion of ANOCA patients (ranging from 75% to 90%) exhibit various underlying causes, such as coronary microvascular dysfunction (CMD), microvascular spasm, endothelial dysfunction, epicardial coronary spasm, and/or myocardial bridging [7,38], emphasizing the critical importance of identifying high-risk ANOCA patients to optimize their further management.

Current research on factors related to adverse outcomes in the ANOCA population is limited. One study attempted to develop a risk tool for chest pain patients with normal coronary arteries to predict favorable outcomes. This tool comprised 10 variables, including age, gender, and the presence of conditions like hypertension, diabetes, or dyslipidemia. However, it is important to note that this study solely relied solely on pretest clinical data and accessed coronary arteries through coronary CTA [18]. In contrast, our predictive model incorporated pre-test indicators, including demographic variables and medical history, with age being one of the key factors. Age is a variable included in many traditional CAD prediction models because it is easily obtainable and reflects the aging of the entire cardiovascular system, including increased arterial stiffness and decreased vascular endothelial function [39,40].

Previous studies have also indicated that several blood biomarkers are associated with unfavorable outcomes in ANOCA patients, including lower levels of HDL-C, elevated levels of soluble urokinase-type plasminogen activator receptor, and high-sensitivity troponin [19,20]. However, none of these

studies conducted comprehensive screening of clinical variables or developed a predictive model. After a thorough screening of blood biomarkers, our predictive model incorporated hemoglobin, serum urea, serum sodium and NT-proBNP, which are rarely reported to be associated with adverse outcomes in ANOCA patients. Anemia, for example, is a common pathological condition involved in the occurrence and development of CAD and heart failure through various mechanisms [41]. It significantly increases the risk of developing CAD and heart failure and is associated with adverse outcomes in these patients [42,43]. Serum urea reflects renal function, which is a crucial factor influencing the cardiovascular system [44]. Previous research has shown that an elevated serum urea levels increase the risk of CAD and serve as a predictive factors for adverse outcomes in CAD and heart failure patients [45,46]. The role of serum sodium in cardiovascular disease is still not fully understood, but several studies have indicated that even mild reductions in serum sodium, even within the normal range, are associated with higher all-cause mortality and cardiovascular mortality in elderly individuals or the general population [47–50]. The underlying mechanisms behind this association require further research. NT-proBNP is a widely recognized marker for heart failure and exhibits strong predictive capabilities for the prognosis of heart failure patients [51]. Previous studies have also demonstrated its ability to predict cardiovascular events and mortality even in community-dwelling or elderly populations without heart failure [52–55].

Our predictive model also considered echocardiographic parameters. Echocardiography is a noninvasive, easily performed, and cost-effective imaging technique that provides comprehensive insights into cardiac structure and function. In our model, left atrial diameter and LVEF were included.

Left atrial enlargement is closely associated with conditions like atrial fibrillation and heart failure, and factors such as hypertension and mitral valve diseases can also lead to left atrial enlargement. It is commonly regarded as a biomarker for adverse cardiovascular outcomes [56–59]. The LVEF serves as one of the diagnostic and classificatory criteria for heart failure, with the latter often signifying the advanced stage of diverse cardiac ailments and indicates an unfavorable prognosis [60,61].

Limitations

This study has several limitations. First, the retrospective design precludes control of treatment strategies and introduces potential selection bias. Second, the study population consisted entirely of individuals from northern China, so caution should be exercised when generalizing the findings of this study to other populations. Third, the inability to subclassify ANOCA patients into those with versus without atherosclerosis represents an important limitation, as pathophysiological differences between these cohorts may contribute to population heterogeneity. However, this aligns with current guideline definitions， and future studies incorporating intracoronary imaging could refine risk stratification. Finally, while the predictive model developed from single-center data has not yet undergone external validation, internal validation confirmed its robust discrimination and calibration, indicating strong performance within the original cohort.

Conclusion

In summary, we conducted a comprehensive evaluation of clinically accessible variables and successfully developed a predictive model for assessing adverse outcomes in angina patients with suspected CAD who do not exhibit obstructive coronary artery stenosis. This nomogram equips clinicians with a valuable tool for risk stratification in ANOCA patients, allowing for optimized management and treatment strategies aimed at improving patient outcomes.

List of abbreviations

ANOCA, angina with nonobstructive coronary arteries

ACU, areas under the curve

ALT, alanine transaminase

AST, aspartate transaminase

LVEF, left ventricular ejection fraction

CAD, coronary artery disease

MI, myocardial infarction

CAG, coronary angiography

CCTA, coronary computed tomography angiography

HDL-C, high-density lipoprotein cholesterol

PCI, percutaneous coronary intervention

CABG, coronary-artery bypass grafting

MACE, major adverse cardiovascular events

Funding

This study was supported by the Key Project of Tianjin Natural Science Foundation (Grant Number: 21JCZDJC01080), Academic Backbone of "Clinical Talent Training and Climbing Plan" of Tianjin Medical University.

Data availability statement

The original data supporting the findings of this study can be obtained from the corresponding author upon reasonable request.

Contributors

L.Z. Conceptualization, Investigation, Methodology, Data curation, Software, Formal analysis, Visualization, Writing – original draft. Z.K.X. Investigation, Data curation, Formal analysis, Writing – review and editing. X.W. Methodology, Writing – review and editing. J.K.Z. Methodology, Writing

– review and editing. S.T.H. Data curation, Writing – review and editing. Y.K.Z. Data curation, Writing – review and editing. T.S.G. Data curation, Writing – review and editing. T.L. Supervision, Validation, Writing – review and editing. S.W.R. Supervision, Validation, Funding acquisition, Writing – review and editing. K.Y.C. Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing. All authors approved the final manuscript. K.Y.C. is responsible for the overall content as guarantor.

Competing interests

This study received infrastructure support from Tianjin Medical University. The funding organization played no role in study design, data collection, analysis, interpretation, manuscript preparation, or publication decisions. All authors declare no additional competing interests.

References

1 Hoorweg BB, Willemsen RT, Cleef LE, *et al.* Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. *Heart Br Card Soc*. 2017;103:1727–32. doi: 10.1136/heartjnl-2016-310905

2 Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145:e153–639. doi: 10.1161/CIR.0000000000001052

3 Virani SS, Newby LK, Arnold SV, *et al.* 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023;148:e9–119. doi: 10.1161/CIR.0000000000001168

4 Fihn SD, Gardin JM, Abrams J, *et al.* 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83

5 Patel MR, Peterson ED, Dai D, *et al.* Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010;362:886–95. doi: 10.1056/NEJMoa0907272

6 Rahman H, Corcoran D, Aetesam-Ur-Rahman M, *et al.* Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. *Heart Br Card Soc*. 2019;105:1536–42. doi: 10.1136/heartjnl-2019-315042

7 Samuels BA, Shah SM, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023;82:1245–63. doi: 10.1016/j.jacc.2023.06.043

8 Shaw LJ, Merz CNB, Pepine CJ, *et al.* The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. *Circulation*. 2006;114:894–904. doi: 10.1161/CIRCULATIONAHA.105.609990

9 Gulati M, Khan N, George M, *et al.* Ischemia with no obstructive coronary artery disease (INOCA): A patient self-report quality of life survey from INOCA international. *Int J Cardiol*. 2023;371:28–39. doi: 10.1016/j.ijcard.2022.09.047

10 Takahashi T, Samuels BA, Li W, *et al.* Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols. *J Am Coll Cardiol*. 2022;79:2367–78. doi: 10.1016/j.jacc.2022.03.385

11 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516

12 Udelson JE, Kelsey MD, Nanna MG, *et al.* Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial. *JAMA Cardiol*. Published Online First: 23 August 2023. doi: 10.1001/jamacardio.2023.2614

13 Gulati M, Levy PD, Mukherjee D, *et al.* 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;144:e368–454. doi: 10.1161/CIR.0000000000001029

14 Knuuti J, Wijns W, Saraste A, *et al.* 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77. doi: 10.1093/eurheartj/ehz425

15 Jordan KP, Timmis A, Croft P, *et al.* Prognosis of undiagnosed chest pain: linked electronic health record cohort study. *BMJ*. 2017;357:j1194. doi: 10.1136/bmj.j1194

16 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J*. 2012;33:734–44. doi: 10.1093/eurheartj/ehr331

17 Gulati M, Cooper-DeHoff RM, McClure C, *et al.* Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009;169:843–50. doi: 10.1001/archinternmed.2009.50

18 Fordyce CB, Douglas PS, Roberts RS, *et al.* Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2017;2:400–8. doi: 10.1001/jamacardio.2016.5501

19 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515

20 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3

21 Sharaf B, Wood T, Shaw L, *et al.* Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. *Am Heart J*. 2013;166:134–41. doi: 10.1016/j.ahj.2013.04.002

22 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted versus observed major adverse cardiac event risk in women with evidence of ischemia and no obstructive coronary artery disease: A report from WISE (women's ischemia syndrome evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi: 10.1161/JAHA.119.013234

23 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*.

2015;350:g7594. doi: 10.1136/bmj.g7594

24 Bairey Merz CN, Pepine CJ, Walsh MN, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. *Circulation*. 2017;135:1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534

25 K T, Js A, As J, *et al.* Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol*. 2018;72. doi: 10.1016/j.jacc.2018.08.1038

26 Powers WJ, Rabinstein AA, Ackerson T, *et al.* Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. *Stroke*. 2019;50:e344–418. doi: 10.1161/STR.0000000000000211

27 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: Pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3

28 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515

29 Johnson BD, Shaw LJ, Pepine CJ, *et al.* Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored women's ischaemia syndrome evaluation (WISE) study. *Eur Heart J*. 2006;27:1408–15. doi: 10.1093/eurheartj/ehl040

30 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516

31 Maddox TM, Stanislawski MA, Grunwald GK, *et al.* Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA*. 2014;312:1754–63. doi: 10.1001/jama.2014.14681

32 Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. *JAMA*. 2005;293:477–84. doi: 10.1001/jama.293.4.477

33 Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. *J Am Coll Cardiol*. 1995;25:1013–8. doi: 10.1016/0735-1097(94)00519-v

34 Kaski JC, Rosano GM, Collins P, *et al.* Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. *J Am Coll Cardiol*. 1995;25:807–14. doi: 10.1016/0735-1097(94)00507-M

35 Sharaf BL, Pepine CJ, Kerensky RA, *et al.* Detailed angiographic analysis of women with

suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–41; A3. doi: 10.1016/s0002-9149(01)01424-2

36 Kenkre TS, Malhotra P, Johnson BD, *et al.* Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). *Circ Cardiovasc Qual Outcomes*. 2017;10:e003863. doi: 10.1161/CIRCOUTCOMES.116.003863

37 Sedlak TL, Lee M, Izadnegahdar M, *et al.* Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. *Am Heart J*. 2013;166:38–44. doi: 10.1016/j.ahj.2013.03.015

38 Smilowitz NR, Prasad M, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023;82:1264–79. doi: 10.1016/j.jacc.2023.06.044

39 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome Evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi: 10.1161/JAHA.119.013234

40 Moreau P, d'Uscio LV, Lüscher TF. Structure and reactivity of small arteries in aging. *Cardiovasc Res*. 1998;37:247–53. doi: 10.1016/s0008-6363(97)00225-3

41 Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. *Coron Artery Dis*. 2018;29:161–7. doi: 10.1097/MCA.0000000000000598

42 Gan T, Hu J, Liu W, *et al.* Causal Association Between Anemia and Cardiovascular Disease: A 2-Sample Bidirectional Mendelian Randomization Study. *J Am Heart Assoc*. 2023;12:e029689. doi: 10.1161/JAHA.123.029689

43 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. *Circulation*. 2003;107:223–5. doi: 10.1161/01.cir.0000052622.51963.fc

44 Herzog CA, Asinger RW, Berger AK, *et al.* Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2011;80:572–86. doi: 10.1038/ki.2011.223

45 Liu F, Ma G, Tong C, *et al.* Elevated blood urea nitrogen-to-creatinine ratio increased the risk of Coronary Artery Disease in patients living with type 2 diabetes mellitus. *BMC Endocr Disord*. 2022;22:50. doi: 10.1186/s12902-022-00954-3

46 Kirtane AJ, Leder DM, Waikar SS, *et al.* Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced

glomerular filtration rates. *J Am Coll Cardiol*. 2005;45:1781–6. doi: 10.1016/j.jacc.2005.02.068

47 He X, Liu C, Chen Y, *et al.* Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. *Can J Cardiol*. 2018;34:999–1003. doi: 10.1016/j.cjca.2018.03.013

48 Wannamethee SG, Shaper AG, Lennon L, *et al.* Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: A population-based cohort study. *Nutr Metab Cardiovasc Dis NMCD*. 2016;26:12–9. doi: 10.1016/j.numecd.2015.07.008

49 Ahn SY, Park YS, Lee SW, *et al.* Association Between Small Decrease in Serum Sodium Concentration within the Normal Range and All-Cause and Cardiovascular Mortality in Elderly Adults over 5 Years. *J Am Geriatr Soc*. 2016;64:510–7. doi: 10.1111/jgs.13937

50 Sajadieh A, Binici Z, Mouridsen MR, *et al.* Mild hyponatremia carries a poor prognosis in community subjects. *Am J Med*. 2009;122:679–86. doi: 10.1016/j.amjmed.2008.11.033

51 Doust JA, Pietrzak E, Dobson A, *et al.* How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ*. 2005;330:625. doi: 10.1136/bmj.330.7492.625

52 McKie PM, Rodeheffer RJ, Cataliotti A, *et al.* Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertens Dallas Tex 1979*. 2006;47:874–80. doi: 10.1161/01.HYP.0000216794.24161.8c

53 Wang TJ, Larson MG, Levy D, *et al.* Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–63. doi: 10.1056/NEJMoa031994

54 Rosenberg J, Schou M, Gustafsson F, *et al.* Prognostic threshold levels of NT-proBNP testing in primary care. *Eur Heart J*. 2009;30:66–73. doi: 10.1093/eurheartj/ehn525

55 Kistorp C, Raymond I, Pedersen F, *et al.* N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA*. 2005;293:1609–16. doi: 10.1001/jama.293.13.1609

56 Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and Clinical Significance. *JACC Cardiovasc Imaging*. 2017;10:65–77. doi: 10.1016/j.jcmg.2016.11.003

57 Krahn AD, Manfreda J, Tate RB, *et al.* The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med*. 1995;98:476–84. doi: 10.1016/S0002-9343(99)80348-9

58 Marsan NA, Maffessanti F, Tamborini G, *et al.* Left atrial reverse remodeling and functional improvement after mitral valve repair in degenerative mitral regurgitation: a real-time 3-

dimensional echocardiography study. *Am Heart J.* 2011;161:314–21. doi: 10.1016/j.ahj.2010.10.029

59 Lloyd-Jones DM, Wang TJ, Leip EP, *et al.* Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004;110:1042–6. doi: 10.1161/01.CIR.0000140263.20897.42

60 Bozkurt B, Coats AJS, Tsutsui H, *et al.* Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail*. 2021;23:352–80. doi: 10.1002/ejhf.2115

61 Heidenreich PA, Bozkurt B, Aguilar D, *et al.* 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e895–1032. doi: 10.1161/CIR.0000000000001063

Figure and table

Figure 1. Flowchart of study participation. CAD, coronary artery disease.

Figure 2. Variable Selection Based on LASSO Regression. (A) Variation Characteristics of Variable Coefficients; (B) Selection Process of Optimal λ Value in LASSO Regression Model Using Cross-Validation.

Figure 3. Nomogram for predicting the probability of 1-, 2-, and 3-year event-free survival of ANOCA patients as assessed by coronary angiography. ALT, alanine transaminase; AST, aspartate transaminase; LVEF, left ventricular ejection fraction.

Figure 4. Receiver operating characteristic curve for the 1-, 2-, and 3-year primary endpoints of the nomogram in the training set (A) and validation set (B). AUC, area under receiver operating characteristic curve.

Figure 5. Calibration plot of predicted 1-, 2-, and 3-year event-free survival based on the nomogram in the training set and validation set. (A–C) Training set; (D–F) Validation set.

Figure 6. Decision curve analysis of the nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the threshold probability, and the y-axis measures the net benefit. The left-slanting straight line shows the net benefit of treating all patients. The bottom horizontal gray line represents the net benefit of not treating any patients. The curve in the middle represents the nomogram.

Figure 7. Kaplan-Meier curves for primary endpoint event-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population.

Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



A



B





A



B





A



B



A



B



Supplement

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
Female, n (%)	3462 (58.3%)	2609 (58.6%)	853 (57.6%)	0.499
Age, years	43.6 (10.8)	43.7 (10.9)	43.5 (10.6)	0.563
Smoking, n (%)	1509 (25.4%)	1126 (25.3%)	383 (25.8%)	0.698
Drinking, n (%)	1883 (31.7%)	1415 (31.8%)	468 (31.6%)	0.909
Hypertension, n (%)	3698 (62.3%)	2802 (62.9%)	896 (60.5%)	0.094
Diabetes mellitus, n (%)	1123 (18.9%)	846 (19.0%)	277 (18.7%)	0.820
Diabetic complications, n (%)	19 (0.32%)	13 (0.29%)	6 (0.40%)	0.595
Dyslipidemia, n (%)	582 (9.81%)	423 (9.50%)	159 (10.7%)	0.185
CKD, n (%)	202 (3.40%)	151 (3.39%)	51 (3.44%)	0.993
SBP, mmHg	136 (19.8)	136 (19.9)	136 (19.7)	0.340
DBP, mmHg	81.9 (12.3)	81.9 (12.4)	81.8 (11.9)	0.757
Heart rate, beats/min	73.8 (15.2)	73.8 (13.9)	73.9 (18.5)	0.798
WBC, 10^9/L	6.67 (2.03)	6.68 (2.01)	6.67 (2.11)	0.969
Hemoglobin, g/L	136 (16.6)	136 (16.6)	136 (16.4)	0.881
Urea, mmol/L	6.09 (2.68)	6.09 (2.72)	6.08 (2.57)	0.831
Serum creatinine, μmol/L	65.9 [55.7; 79.8]	66.2 [55.7; 79.7]	65.4 [55.5; 80.0]	0.748
Uric acid, μmol/L	335 (100)	335 (101)	335 (99.0)	0.889
Serum sodium, mmol/L	142 (3.51)	142 (3.32)	142 (4.01)	0.829
Serum potassium, mmol/L	4.12 (0.56)	4.12 (0.47)	4.13 (0.76)	0.649
Serum chloride, mmol/L	106 (3.37)	106 (3.42)	106 (3.21)	0.515
Anion gap, mmol/L	14.0 (2.40)	13.9 (2.40)	14.0 (2.42)	0.844

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
Total protein, g/L	68.2 (6.41)	68.2 (6.37)	68.2 (6.54)	0.968
Albumin, g/L	42.4 (3.88)	42.4 (3.87)	42.3 (3.91)	0.406
Globulin, g/L	25.9 (4.19)	25.8 (4.16)	25.9 (4.30)	0.353
ALT, U/L	17.7 [13.0; 24.7]	17.8 [13.1; 24.8]	17.6 [12.6; 24.5]	0.169
AST, U/L	17.7 [14.6; 21.6]	17.8 [14.6; 21.6]	17.5 [14.6; 21.5]	0.341
ALT/AST ratio	1.06 (0.41)	1.05 (0.41)	1.07 (0.42)	0.157
Total bilirubin, μmol/L	13.6 (6.67)	13.6 (6.81)	13.4 (6.23)	0.257
Indirect Bilirubin, μmol/L	9.63 (4.69)	9.67 (4.75)	9.51 (4.53)	0.242
Direct Bilirubin, μmol/L	3.40 [2.30; 4.60]	3.40 [2.30; 4.60]	3.40 [2.40; 4.60]	0.611
Alkaline phosphatase, U/L	76.5 (23.6)	76.5 (23.6)	76.6 (23.7)	0.820
Total cholesterol, mmol/L	4.75 (1.12)	4.75 (1.13)	4.74 (1.08)	0.919
Triglycerides, mmol/L	1.63 (1.11)	1.62 (1.11)	1.65 (1.10)	0.485
HDL-C, mmol/L	1.22 (0.31)	1.22 (0.32)	1.20 (0.30)	0.083
LDL-C, mmol/L	2.97 (0.88)	2.97 (0.88)	2.98 (0.87)	0.498
VLDL-C, mmol/L	0.56 (0.37)	0.56 (0.39)	0.56 (0.30)	0.627
Troponin I, ng/ml	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.536
NT-proBNP, ng/L	83.7 [35.1; 266]	83.0 [34.3; 265]	86.7 [38.0; 269]	0.415
CKMB, U/L	12.1 [9.30; 14.7]	12.0 [9.24; 14.7]	12.3 [9.30; 14.7]	0.529
D-Dimer, μg/L	276 [2.34; 434]	274 [1.78; 427]	282 [4.65; 457]	0.110
Glucose, mmol/L	6.81 (2.48)	6.82 (2.45)	6.78 (2.56)	0.579
Left atrial diameter, mm	38.7 (5.24)	38.7 (5.28)	38.6 (5.11)	0.331

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
LVEDD, mm	47.4 (4.46)	47.4 (4.51)	47.3 (4.28)	0.373
LVESD, mm	26.9 (5.62)	26.9 (5.65)	27.0 (5.52)	0.737
RVEDD, mm	20.8 (3.37)	20.7 (3.61)	20.8 (2.53)	0.623
LVEF, %	61.7 (6.75)	61.7 (6.77)	61.6 (6.70)	0.486
Event-free survival time, days	635 (403)	633 (402)	641 (406)	0.512
Death, n (%)	106 (1.79%)	78 (1.75%)	28 (1.89%)	0.816
MI endpoint, n (%)	33 (0.56%)	21 (0.47%)	12 (0.81%)	0.189
Stroke endpoint, n (%)	11 (0.19%)	6 (0.13%)	5 (0.34%)	0.156
MACE, n (%)	82 (1.38%)	64 (1.44%)	18 (1.21%)	0.611
Primary endpoint, n (%)	145 (2.44%)	105 (2.36%)	40 (2.70%)	0.523

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; CKMB, creatine kinase-MB; LVEDD, left ventricular-end-diastolic diameter; LVESD, left ventricular-end-systolic diameter; RVEDD, right ventricular-end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACE, major adverse cardiovascular events.



Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population



Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

BMJ Open

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2024-092614.R2
Article Type:	Original research
Date Submitted by the Author:	23-Apr-2025
Complete List of Authors:	Zhu, Lei; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Xue, Zheng-Kai; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Wu, Xue; University of California San Francisco, Institute for Global Health Sciences Zhang, JingKun; University of California San Francisco, Cardiovascular Research Institute Hu, Su-Tao; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Zhang, Yu-Kun; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Gu, Tian-Shu; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Liu, Tong; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Rha, Seung-Woon; Korea University Guro Hospital, Cardiovascular Center Chen, Kang-Yin; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Angina Pectoris, Coronary heart disease < CARDIOLOGY, Prognosis

I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

Authors: Lei Zhu[1], Zheng-Kai Xue[1], Xue Wu[2], Jing-Kun Zhang[3], Su-Tao Hu [1], Yu-Kun Zhang[1], Tian-Shu Gu[1], Tong Liu[1], Seung-Woon Rha[4], Kang-Yin Chen[1*]

Affiliations: [1] Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China

[2] Institute for Global Health Sciences, University of California, San Francisco, CA, USA

[3] Cardiovascular Research Institute, University of California San Francisco, CA, USA

[4] Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.

***Corresponding author:** Kang-Yin Chen, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China (chenkangyin@vip.126.com)

Word count: 3081

Abstract

Objectives

To develop and validate a risk prediction model for adverse outcomes in patients with angina with nonobstructive coronary arteries (ANOCA) confirmed by invasive coronary angiography.

Design

Retrospective cohort study.

Setting

A tertiary cardiovascular care center in China.

Participants

From 17,816 consecutive patients undergoing coronary angiography for suspected coronary artery disease, 5,934 met ANOCA criteria after rigorous exclusion: (1) significant stenosis (≥50% luminal narrowing), (2) established coronary artery disease history, (3) incomplete baseline/follow-up data, (4) non-cardiovascular life-limiting conditions.

primary and secondary outcome measures

The primary outcome was a composite of all-cause death, nonfatal myocardial infarction (MI), stroke, and repeat percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG). The secondary outcome was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG.

Results

The derivation cohort (n=4,452) and validation cohort (n=1,482) demonstrated comparable baseline characteristics. The nomogram incorporated eight prognosticators: age, hemoglobin, serum urea, serum sodium, alanine aminotransferase (ALT) / aspartate aminotransferase (AST) ratio, N-terminal pro-B-type natriuretic peptide (NT-proBNP), left atrial diameter, and left ventricular ejection fraction (LVEF). The prediction model showed robust discrimination for primary endpoint, achieving area under the curve (AUC) values of 0.82 (1-year), 0.90 (2-year), and 0.89 (3-year) in the derivation cohort, with corresponding validation cohort AUCs of 0.75, 0.77, and 0.78. Calibration plots revealed close alignment between predicted and actual event-free survival probabilities in both cohorts. Risk stratification identified two distinct prognostic groups with significant survival differences (log-rank $p < 0.0001$).

Conclusions

This predictive model integrates routinely available clinical parameters to accurately stratify mortality and cardiovascular risk in ANOCA patients, providing a potential valuable decision-support tool for personalized therapeutic strategies.

Strengths and limitations of this study

- This study utilized a large sample size (n=5934) with rigorous internal validation through training and testing cohorts.
- Leveraged LASSO-penalized Cox regression with 10-fold cross-validation to optimize model

generalizability.

- The nomogram integrates routinely available clinical variables, enhancing clinical applicability.
- Limitations include the retrospective design, which may introduce selection bias.
- Data were derived from a single center, potentially limiting generalizability.

Key word

Angina, coronary artery disease, MINOCA, prognosis, nomogram.

Backgrounds

Chest pain is a common symptom among patients seeking medical services, often raising concerns about potentially life-threatening conditions such as coronary artery disease (CAD) [1,2]. Timely and accurate diagnostic assessments, including electrocardiography, coronary computed tomography angiography (CCTA), and coronary angiography (CAG), are frequently recommended for individuals presenting with chest pain to rule out severe conditions such as myocardial infarction (MI) [3,4]. However, in the cohort of patients undergoing diagnostic workup, approximately half exhibit nonobstructive coronary arteries (stenosis less than 50%)[5,6], a condition known as angina with nonobstructive coronary arteries (ANOCA) [7].

ANOCA patients often seek medical care due to symptoms and undergo repetitive invasive examinations, leading to significant healthcare resource utilization and imposing individual burdens and additional risks [8–10]. In a randomized controlled trial involving over 10,000 patients suspected of CAD with intermediate pretest likelihood, only approximately 12% of them yielded a positive result in the final coronary artery functional tests [11]. Patients with a low pretest probability exhibit an exceedingly low positivity rate in diagnostic workup and experience fewer adverse outcomes [12]. Therefore, clinical guidelines recommend delaying diagnostic testing for patients at low risk for CAD[13,14]. However, patients without obstructive coronary arteries confirmed by CAG or CCTA have been observed to experience more adverse outcomes compared to the general population[15–17]. Identifying high-risk individuals in ANOCA patients remains a challenge.

There is limited research on predicting adverse outcomes in ANOCA patients confirmed through CAG or CCTA. Some studies have validated the utility of specific pretest indicators, such as age, sex, and traditional cardiovascular disease risk factors(e.g., hypertension), to identify low-risk ANOCA patients [18]. However, several investigations have shown that specific blood biomarkers, including high-sensitivity troponin and lower high-density lipoprotein cholesterol (HDL-C) levels, operate as independent predictive factors for poor prognosis in ANOCA patients, adding prognostic value[19]. To date, comprehensive studies that screen noninvasive indicators and develop a prognostic model are lacking, and most previous studies are reliant on data derived from the Women's Ischemia Syndrome Evaluation (WISE) study[19–21], which exclusively includes female participants. One study also used WISE data to validate the effectiveness of some risk scores originally designed for other populations, such as the Atherosclerotic Cardiovascular Disease (ASCVD) score, in predicting adverse outcomes in ANOCA patients, but the results showed suboptimal performance[22]. Therefore, it is necessary to develop a predictive model based on non-invasive indicators to forecast adverse outcomes in ANOCA patients of both sexes. This study aims to bridge this gap to optimize clinical decision-making and patient management.

Method

Study Population

This is a retrospective cohort study that consecutively enrolled patients who presented with suspected

symptoms of CAD and underwent coronary angiography at the department of cardiology or emergency department of the Second Hospital of Tianjin Medical University between January 2019 and June 2023. The Second Hospital of Tianjin Medical University is a cardiac center serving the northern Chinese city of Tianjin and its surrounding regions. This study adheres to the principles outlined in the TRIPOD statement [23].

ANOCA patients were defined as angina with nonobstructive epicardial coronary arteries (stenosis <50%), adhering to current expert consensus[7]. Patients meeting the following criteria were excluded from the study: (1) patients with acute coronary syndrome or obstructive coronary arteries (defined as a luminal stenosis of ≥50% in a major epicardial coronary artery[7,24]); (2) patients with a prior diagnosis of CAD, history of percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG); (3) individuals with severe liver or kidney dysfunction, malignancies, or other non-cardiovascular conditions significantly affecting life expectancy; (4) those with substantial missing baseline data; and (5) patients lost to follow-up. This study received approval from the Ethics Committee of the Second Hospital of Tianjin Medical University, with a waiver for written informed consent granted for the retrospective use of fully anonymized clinical data (No. KY2025K008).

Clinical Data Collection

Patient data were retrospectively obtained from electronic medical records, including demographic information, medical history, vital sign data, laboratory parameters, echocardiographic data, coronary

angiography findings and other relevant details.

Follow-Up and Endpoints

A dedicated follow-up team conducted systematic post-discharge surveillance through a standardized protocol, with scheduled assessments at 30 days, 3 months, 6 months, and annually thereafter. Data collection employed a multimodal approach: (1) comprehensive electronic health record review, (2) cross-referencing with regional death registries, (3) and telephone or email interviews. The observational window for this analysis was finalized on August 1, 2023. Two board-certified cardiologists (L.Z. and Z.K.X., each with >5 years clinical experience) independently evaluated all events using standardized diagnostic criteria[25,26]. For discrepancies in event classification, an adjudication committee comprising two senior interventional cardiologists (T.L. and K.Y.C., both with >20 years catheterization laboratory experience) conducted final arbitration through consensus review.

The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or CABG during follow-up. The secondary endpoint was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG during follow-up. The composite endpoint was selected based on its established utility in prognostic studies of ANOCA [22,27–29].

Statistical Analysis

For the small amount of missing data in smoking and alcohol consumption history, multiple imputation was performed using the MICE package (Multiple Imputation by Chained Equations package). To establish a reliable model, the entire study cohort was randomly stratified into two subsets, a training set and a validation set, with a ratio of 0.75 to 0.25, respectively. The training set was used to generate the predictive model, while the validation set was utilized for model internal validation.

Categorical variables were described as frequencies and percentages, with group differences assessed using the chi-square test or Fisher's exact test as applicable. Continuous variables were expressed as either the mean ± standard deviation (SD) or median [interquartile range, IQR], and group comparisons were conducted using the t test or Kruskal–Wallis test as appropriate. Variables with variance inflation factor (VIF) ≥5 were excluded prior to LASSO regression to mitigate multicollinearity. The variables selected through LASSO regression were incorporated into the Cox proportional hazards regression model, and a nomogram was generated based on the Cox regression analysis model. The discriminative ability of the predictive model was evaluated using area under the curve (AUC). The model's calibration was assessed through the calibration curve. Additionally, decision curve analysis was employed to evaluate the clinical utility of the nomogram.

The total score for each patient was calculated based on the nomogram, and the study population was stratified into high-risk and low-risk groups according to the score corresponding to the 3-year 95% event-free survival probability. Event-free survival for the high- and low-risk groups in the training

and validation sets was estimated by Kaplan–Meier method and compared with the log-rank test. All statistical analyses were performed with R software version 4.3.1 (R Foundation for Statistical Computing). All statistical tests were two- tailed, with a significance level set at $P<0.05$.

Patient and public involvement

None.

Result

Study Population and Patient Characteristics

Out of a consecutive cohort of 17,816 patients who underwent coronary angiography for suspected coronary artery disease, 9,883 individuals with significant coronary artery stenosis and 1,816 patients with a documented history of coronary heart disease were excluded. An additional 131 individuals were excluded due to missing baseline or follow-up data, and 52 patients with severe conditions such as malignant tumors were also excluded. of the final analysis included 5,934 patients with negative coronary angiography results (**Figure 1**).

The mean age of the overall cohort was 43.6 ± 10.8 years, with 58.3% being female, and the median follow-up time was 631 [270, 972] days. Detailed baseline data are provided in **Supplementary Table 1**. During the follow-up period, 145 (2.44%) patients had primary endpoint events, 82 (1.38%) had MACE, 106 (1.79%) had all-cause death, 33 (0.56%) had MI, and 11 (0.19%) had a stroke. The

Kaplan-Meier method was employed to estimate the survival without various adverse events for the total study population (**Supplementary Figure 1**).

Nomogram built based on LASSO-COX regression

The entire cohort was randomly divided into a training cohort consisting of 4,452 patients and a validation cohort comprising 1,482 patients. There were no statistically significant differences in the collected variables between these two groups (**Supplementary Table 1**). LASSO regression was employed to select variables with the strongest correlation to the primary endpoint. As the regularization parameter (λ) increased, certain coefficients were reduced to zero, effectively eliminating those variables from the model (**Figure 2A**). We used a tenfold cross-validation approach to identify the optimal model. Due to the relatively limited number of cases undergoing primary endpoint events in the validation cohort (145), we employed the one standard error (1-se) rule, resulting in eight selected variables (**Figure 2B**). These variables were incorporated into a Cox proportional hazards regression model, with results presented in **Table 1**. All models satisfied proportional hazards assumptions (global test p=0.057). A nomogram was developed based on the Cox regression model, with the regression coefficients of these factors amalgamated into a scoring system, ranging from 0 to 100(**Figure 3**). For example, an 81-year-old male patient with a hemoglobin level of 92 g/L, serum urea of 14.1 mmol/L, serum sodium of 145.6 mmol/L, an ALT/AST ratio of 1.68, NT-proBNP at 272 ng/L, left atrial diameter of 38.83 millimeters, and an LVEF of 62% received a total score of 115. The 1-year, 2-year and 3-year event-free survival rates were 99.5%, 96.2% and 89.0%, respectively.

Table 1. Prediction of event-free survival probability using the Cox proportional hazards regression model based on LASSO regression.

Variable	coefficients	z score	HR	95%CI	p value
Age	0.043	4.167	1.044	0.023, 0.063	<0.001
Hemoglobin	-0.015	-2.871	0.985	-0.026, -0.005	0.004
Urea	0.074	3.947	1.077	0.037, 0.111	<0.001
Serum sodium	-0.074	-5.694	0.929	-0.1, -0.049	<0.001
ALT/AST ratio	0.444	2.439	1.559	0.087, 0.8	0.015
NT-proBNP	0	2.094	1	0, 0	0.036
Left atrial diameter	0.076	5.959	1.079	0.051, 0.8	<0.001
LVEF	-0.022	-2.289	0.979	-0.04, -0.003	0.022

HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase; NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricular ejection fraction.

Discrimination and calibration of the nomogram

The discriminative ability of the model was assessed by plotting receiver operating characteristic curves. In the training set, the AUC for 1-, 2-, and 3-year predictions was 0.82, 0.90, and 0.89, respectively. In the validation set, the corresponding AUC for 1-, 2-, and 3-year predictions were 0.75, 0.77, and 0.78, respectively (**figure 4**).

Figure 5 illustrates calibration plots for the models predicting 1-, 2-, and 3-year survival in both the training and validation datasets. In well-calibrated models, the points closely align with the ideal 45-degree line, indicating that predicted survival closely matches observed survival and demonstrating

good model calibration.

Decision Curve

Decision curve analysis was employed to evaluate the potential improvement in clinical outcomes through nomogram-assisted decision-making for patients. As illustrated in **Figure 6**, the results reveal that across a broad spectrum of threshold probabilities in both the training and testing cohorts, utilizing the nomogram for predicting the 2-year or 3-year event-free survival probability offers a more significant net benefit when compared to strategies of 'treat all' or 'treat none.' These findings underscore the clinical utility of the nomogram.

Risk stratification

Considering that the study population consists of low-risk patients with non-obstructive coronary artery stenosis, the threshold for further risk stratification was set at a higher event-free survival probability, specifically a score of 104 points corresponding to the 95% 3-year event-free survival probability as determined by the nomogram. Individuals scoring below this threshold were categorized as low-risk, while those scoring equal to or above it were classified as high-risk. Kaplan-Meier curves depicting event-free survival were created for the two risk groups in the training and validation sets (**Figure 7**). Furthermore, MACE-event free survival of these groups is shown in **Supplementary Figure 2**. These results consistently demonstrated the model's efficacy in patient risk stratification.

Discussion

This study focused on patients initially suspected of having CAD but who were found to have nonobstructive coronary arteries following coronary angiography. A wide range of variables, including demographic information, vital signs, laboratory parameters, and echocardiographic measurements, were meticulously examined. Ultimately, 8 key variables, namely age, hemoglobin levels, serum urea, serum sodium levels, ALT/AST ratio, NT-proBNP levels, left atrial diameter, and LVEF, were identified. The study successfully developed a nomogram to predict the probability of event-free survival for these patients, demonstrating excellent discriminatory and calibration abilities in both the training and validation sets. The utilization of this predictive model in clinical practice empowers healthcare providers to conduct more precise risk stratification, particularly for individuals initially classified as low-risk, thereby improving diagnostic, management, and treatment strategies and ultimately enhancing patient outcomes.

In clinical practice, a substantial number of patients with potential cardiac issues, such as chest pain, actively seek medical attention in both outpatient and emergency department settings. In the United Kingdom, for instance, approximately 1-2% of adults consult primary care facilities when experiencing chest pain for the first time [15]. Similarly, millions of individuals in the United States undergo stress tests in outpatient clinics each year for undiagnosed heart conditions [30]. However, research has

consistently shown that following diagnostic assessments like coronary angiography, approximately 50% of patients do not exhibit obstructive coronary artery stenosis [5,16,24,31]. Traditionally, such patients were often considered to have a favorable prognosis and no significant cardiac conditions , potentially resulting in the omission of further diagnostic measures and therapeutic interventions [32–34]. However, recent research has indicated that these patients face a significantly elevated risk of adverse outcomes compared to the general population. The WISE study revealed that at over a 10-year follow-up, patients without obstructive coronary stenosis on coronary angiography had rates of cardiovascular death and MI of 6.7% and 12.8%, respectively, underscoring the heightened risk among female ANOCA patients [21,35,36]. Other studies have also demonstrated that ANOCA patients, regardless of their gender, face an increased risk of experiencing CAD-related outcomes compared to the general population[16,31,37].

Our findings from this study indicate that ANOCA patients tend to be younger, with an average age of 43.6 years, and a higher proportion of them are female (58.3%) [7]. During a median follow-up period of 2 years, the rates of all-cause death, MI, and stroke were 1.79%, 0.56%, and 0.19%, respectively. These findings align with a previous study reporting 1-year MI rates ranging from 0.11% to 0.59% and 1-year mortality rates ranging from 1.38% to 2.3% [31]. Our research further supports the characterization of ANOCA patients and provides additional evidence of their elevated risk for adverse outcomes across diverse populations.

While clinical guidelines suggest risk stratification of chest pain patients and deferring testing for those

with a low likelihood of CAD, this strategy may inadvertently exclude high-risk ANOCA patients who require further assessment and appropriate therapeutic interventions [13,14]. As highlighted in a recent review, a significant proportion of ANOCA patients (ranging from 75% to 90%) exhibit various underlying causes, such as coronary microvascular dysfunction, microvascular spasm, endothelial dysfunction, epicardial coronary spasm, and/or myocardial bridging [7,38], emphasizing the critical importance of identifying high-risk ANOCA patients to optimize their further management.

Current research on factors related to adverse outcomes in the ANOCA population is limited. One study attempted to develop a risk tool for chest pain patients with normal coronary arteries to predict favorable outcomes. This tool comprised 10 variables, including age, gender, and the presence of conditions like hypertension, diabetes, or dyslipidemia. However, it is important to note that this study solely relied solely on pretest clinical data and accessed coronary arteries through CCTA [18]. In contrast, our predictive model incorporated pre-test indicators, including demographic variables and medical history, with age being one of the key factors. Age is a variable included in many traditional CAD prediction models because it is easily obtainable and reflects the aging of the entire cardiovascular system, including increased arterial stiffness and decreased vascular endothelial function [39,40].

Previous studies have also indicated that several blood biomarkers are associated with unfavorable outcomes in ANOCA patients, including lower levels of HDL-C, elevated levels of soluble urokinase-type plasminogen activator receptor, and high-sensitivity troponin [19,20]. However, none of these

studies conducted comprehensive screening of clinical variables or developed a predictive model. After a thorough screening of blood biomarkers, our predictive model incorporated hemoglobin, serum urea, serum sodium and NT-proBNP, which are rarely reported to be associated with adverse outcomes in ANOCA patients. Anemia, for example, is a common pathological condition involved in the occurrence and development of CAD and heart failure through various mechanisms [41]. It significantly increases the risk of developing CAD and heart failure and is associated with adverse outcomes in these patients [42,43]. Serum urea reflects renal function, which is a crucial factor influencing the cardiovascular system [44]. Previous research has shown that an elevated serum urea levels increase the risk of CAD and serve as a predictive factors for adverse outcomes in CAD and heart failure patients [45,46]. The role of serum sodium in cardiovascular disease is still not fully understood, but several studies have indicated that even mild reductions in serum sodium, even within the normal range, are associated with higher all-cause mortality and cardiovascular mortality in elderly individuals or the general population [47–50]. The underlying mechanisms behind this association require further research. NT-proBNP is a widely recognized marker for heart failure and exhibits strong predictive capabilities for the prognosis of heart failure patients [51]. Previous studies have also demonstrated its ability to predict cardiovascular events and mortality even in community-dwelling or elderly populations without heart failure [52–55].

Our predictive model also considered echocardiographic parameters. Echocardiography is a noninvasive, easily performed, and cost-effective imaging technique that provides comprehensive insights into cardiac structure and function. In our model, left atrial diameter and LVEF were included.

Left atrial enlargement is closely associated with conditions like atrial fibrillation and heart failure, and factors such as hypertension and mitral valve diseases can also lead to left atrial enlargement. It is commonly regarded as a biomarker for adverse cardiovascular outcomes [56–59]. The LVEF serves as one of the diagnostic and classificatory criteria for heart failure, with the latter often signifying the advanced stage of diverse cardiac ailments and indicates an unfavorable prognosis [60,61].

Limitations

This study has several limitations. First, the retrospective design precludes control of treatment strategies and introduces potential selection bias. Second, the study population consisted entirely of individuals from northern China, so caution should be exercised when generalizing the findings of this study to other populations. Third, the inability to subclassify ANOCA patients into those with versus without atherosclerosis represents an important limitation, as pathophysiological differences between these cohorts may contribute to population heterogeneity. However, this aligns with current guideline definitions， and future studies incorporating intracoronary imaging could refine risk stratification. Finally, while the predictive model developed from single-center data has not yet undergone external validation, internal validation confirmed its robust discrimination and calibration, indicating strong performance within the original cohort.

Conclusion

In summary, we conducted a comprehensive evaluation of clinically accessible variables and successfully developed a predictive model for assessing adverse outcomes in angina patients with suspected CAD who do not exhibit obstructive coronary artery stenosis. This nomogram equips clinicians with a valuable tool for risk stratification in ANOCA patients, allowing for optimized management and treatment strategies aimed at improving patient outcomes.

List of abbreviations

ANOCA, angina with nonobstructive coronary arteries

MI, myocardial infarction

PCI, percutaneous coronary intervention

CABG, coronary-artery bypass grafting

MACE, major adverse cardiovascular events

ALT, alanine transaminase

AST, aspartate transaminase

NT-proBNP, N-terminal pro-B-type natriuretic peptide

LVEF, left ventricular ejection fraction

AUC, area under the curve

CAD, coronary artery disease

CAG, coronary angiography

CCTA, coronary computed tomography angiography

HDL-C, high-density lipoprotein cholesterol

SD, standard deviation

IQR, interquartile range

VIF, variance inflation factor

Funding

This study was supported by the Key Project of Tianjin Natural Science Foundation (Grant Number: 21JCZDJC01080), Academic Backbone of "Clinical Talent Training and Climbing Plan" of Tianjin Medical University.

Data availability statement

The original data supporting the findings of this study can be obtained from the corresponding author upon reasonable request.

Contributors

L.Z. Conceptualization, Investigation, Methodology, Data curation, Software, Formal analysis,

Visualization, Writing – original draft. Z.K.X. Investigation, Data curation, Formal analysis, Writing – review and editing. X.W. Methodology, Writing – review and editing. J.K.Z. Methodology, Writing – review and editing. S.T.H. Data curation, Writing – review and editing. Y.K.Z. Data curation, Writing – review and editing. T.S.G. Data curation, Writing – review and editing. T.L. Supervision, Validation, Writing – review and editing. S.W.R. Supervision, Validation, Funding acquisition, Writing – review and editing. K.Y.C. Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review and editing. All authors approved the final manuscript. K.Y.C. is responsible for the overall content as guarantor.

Competing interests

This study received infrastructure support from Tianjin Medical University. The funding organization played no role in study design, data collection, analysis, interpretation, manuscript preparation, or publication decisions. All authors declare no additional competing interests.

References

1 Hoorweg BB, Willemsen RT, Cleef LE, *et al.* Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. *Heart Br Card Soc*. 2017;103:1727–32. doi: 10.1136/heartjnl-2016-310905

2 Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145:e153–639. doi: 10.1161/CIR.0000000000001052

3 Virani SS, Newby LK, Arnold SV, *et al.* 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023;148:e9–119. doi: 10.1161/CIR.0000000000001168

4 Fihn SD, Gardin JM, Abrams J, *et al.* 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*. 2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83

5 Patel MR, Peterson ED, Dai D, *et al.* Low diagnostic yield of elective coronary angiography. *N Engl J Med*. 2010;362:886–95. doi: 10.1056/NEJMoa0907272

6 Rahman H, Corcoran D, Aetesam-Ur-Rahman M, *et al.* Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. *Heart Br Card Soc*. 2019;105:1536–42. doi: 10.1136/heartjnl-2019-315042

7 Samuels BA, Shah SM, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023;82:1245–63. doi: 10.1016/j.jacc.2023.06.043

8 Shaw LJ, Merz CNB, Pepine CJ, *et al.* The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. *Circulation*. 2006;114:894–904. doi: 10.1161/CIRCULATIONAHA.105.609990

9 Gulati M, Khan N, George M, *et al.* Ischemia with no obstructive coronary artery disease (INOCA): A patient self-report quality of life survey from INOCA international. *Int J Cardiol*. 2023;371:28–39. doi: 10.1016/j.ijcard.2022.09.047

10 Takahashi T, Samuels BA, Li W, *et al.* Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols. *J Am Coll Cardiol*. 2022;79:2367–78. doi: 10.1016/j.jacc.2022.03.385

11 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516

12 Udelson JE, Kelsey MD, Nanna MG, *et al.* Deferred Testing in Stable Outpatients With Suspected

Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial. *JAMA Cardiol*. Published Online First: 23 August 2023. doi: 10.1001/jamacardio.2023.2614

13 Gulati M, Levy PD, Mukherjee D, *et al.* 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2021;144:e368–454. doi: 10.1161/CIR.0000000000001029

14 Knuuti J, Wijns W, Saraste A, *et al.* 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77. doi: 10.1093/eurheartj/ehz425

15 Jordan KP, Timmis A, Croft P, *et al.* Prognosis of undiagnosed chest pain: linked electronic health record cohort study. *BMJ*. 2017;357:j1194. doi: 10.1136/bmj.j1194

16 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J*. 2012;33:734–44. doi: 10.1093/eurheartj/ehr331

17 Gulati M, Cooper-DeHoff RM, McClure C, *et al.* Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009;169:843–50. doi: 10.1001/archinternmed.2009.50

18 Fordyce CB, Douglas PS, Roberts RS, *et al.* Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2017;2:400–8. doi: 10.1001/jamacardio.2016.5501

19 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515

20 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3

21 Sharaf B, Wood T, Shaw L, *et al.* Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. *Am Heart J*. 2013;166:134–41. doi: 10.1016/j.ahj.2013.04.002

22 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted versus observed major adverse cardiac event risk in women with evidence of ischemia and no obstructive coronary artery disease: A report from WISE (women's ischemia syndrome evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi:

10.1161/JAHA.119.013234

23 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*. 2015;350:g7594. doi: 10.1136/bmj.g7594

24 Bairey Merz CN, Pepine CJ, Walsh MN, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. *Circulation*. 2017;135:1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534

25 K T, Js A, As J, *et al.* Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol*. 2018;72. doi: 10.1016/j.jacc.2018.08.1038

26 Powers WJ, Rabinstein AA, Ackerson T, *et al.* Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. *Stroke*. 2019;50:e344–418. doi: 10.1161/STR.0000000000000211

27 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: Pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3

28 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515

29 Johnson BD, Shaw LJ, Pepine CJ, *et al.* Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored women's ischaemia syndrome evaluation (WISE) study. *Eur Heart J*. 2006;27:1408–15. doi: 10.1093/eurheartj/ehl040

30 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516

31 Maddox TM, Stanislawski MA, Grunwald GK, *et al.* Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA*. 2014;312:1754–63. doi: 10.1001/jama.2014.14681

32 Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. *JAMA*. 2005;293:477–84. doi: 10.1001/jama.293.4.477

33 Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. *J Am Coll Cardiol*. 1995;25:1013–8. doi: 10.1016/0735-1097(94)00519-v

34 Kaski JC, Rosano GM, Collins P, *et al.* Cardiac syndrome X: clinical characteristics and left

ventricular function. Long-term follow-up study. *J Am Coll Cardiol*. 1995;25:807–14. doi: 10.1016/0735-1097(94)00507-M

35 Sharaf BL, Pepine CJ, Kerensky RA, *et al.* Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–41; A3. doi: 10.1016/s0002-9149(01)01424-2

36 Kenkre TS, Malhotra P, Johnson BD, *et al.* Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). *Circ Cardiovasc Qual Outcomes*. 2017;10:e003863. doi: 10.1161/CIRCOUTCOMES.116.003863

37 Sedlak TL, Lee M, Izadnegahdar M, *et al.* Sex differences in clinical outcomes in patients with stable angina and no obstructive coronary artery disease. *Am Heart J*. 2013;166:38–44. doi: 10.1016/j.ahj.2013.03.015

38 Smilowitz NR, Prasad M, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2023;82:1264–79. doi: 10.1016/j.jacc.2023.06.044

39 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome Evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi: 10.1161/JAHA.119.013234

40 Moreau P, d'Uscio LV, Lüscher TF. Structure and reactivity of small arteries in aging. *Cardiovasc Res*. 1998;37:247–53. doi: 10.1016/s0008-6363(97)00225-3

41 Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. *Coron Artery Dis*. 2018;29:161–7. doi: 10.1097/MCA.0000000000000598

42 Gan T, Hu J, Liu W, *et al.* Causal Association Between Anemia and Cardiovascular Disease: A 2-Sample Bidirectional Mendelian Randomization Study. *J Am Heart Assoc*. 2023;12:e029689. doi: 10.1161/JAHA.123.029689

43 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. *Circulation*. 2003;107:223–5. doi: 10.1161/01.cir.0000052622.51963.fc

44 Herzog CA, Asinger RW, Berger AK, *et al.* Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*. 2011;80:572–86. doi: 10.1038/ki.2011.223

45 Liu F, Ma G, Tong C, *et al.* Elevated blood urea nitrogen-to-creatinine ratio increased the risk of Coronary Artery Disease in patients living with type 2 diabetes mellitus. *BMC Endocr Disord*.

2022;22:50. doi: 10.1186/s12902-022-00954-3

46 Kirtane AJ, Leder DM, Waikar SS, *et al.* Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol*. 2005;45:1781–6. doi: 10.1016/j.jacc.2005.02.068

47 He X, Liu C, Chen Y, *et al.* Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. *Can J Cardiol*. 2018;34:999–1003. doi: 10.1016/j.cjca.2018.03.013

48 Wannamethee SG, Shaper AG, Lennon L, *et al.* Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: A population-based cohort study. *Nutr Metab Cardiovasc Dis NMCD*. 2016;26:12–9. doi: 10.1016/j.numecd.2015.07.008

49 Ahn SY, Park YS, Lee SW, *et al.* Association Between Small Decrease in Serum Sodium Concentration within the Normal Range and All-Cause and Cardiovascular Mortality in Elderly Adults over 5 Years. *J Am Geriatr Soc*. 2016;64:510–7. doi: 10.1111/jgs.13937

50 Sajadieh A, Binici Z, Mouridsen MR, *et al.* Mild hyponatremia carries a poor prognosis in community subjects. *Am J Med*. 2009;122:679–86. doi: 10.1016/j.amjmed.2008.11.033

51 Doust JA, Pietrzak E, Dobson A, *et al.* How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ*. 2005;330:625. doi: 10.1136/bmj.330.7492.625

52 McKie PM, Rodeheffer RJ, Cataliotti A, *et al.* Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertens Dallas Tex 1979*. 2006;47:874–80. doi: 10.1161/01.HYP.0000216794.24161.8c

53 Wang TJ, Larson MG, Levy D, *et al.* Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–63. doi: 10.1056/NEJMoa031994

54 Rosenberg J, Schou M, Gustafsson F, *et al.* Prognostic threshold levels of NT-proBNP testing in primary care. *Eur Heart J*. 2009;30:66–73. doi: 10.1093/eurheartj/ehn525

55 Kistorp C, Raymond I, Pedersen F, *et al.* N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA*. 2005;293:1609–16. doi: 10.1001/jama.293.13.1609

56 Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and Clinical Significance. *JACC Cardiovasc Imaging*. 2017;10:65–77. doi: 10.1016/j.jcmg.2016.11.003

57 Krahn AD, Manfreda J, Tate RB, *et al.* The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med*. 1995;98:476–84. doi:

10.1016/S0002-9343(99)80348-9

58 Marsan NA, Maffessanti F, Tamborini G, *et al.* Left atrial reverse remodeling and functional improvement after mitral valve repair in degenerative mitral regurgitation: a real-time 3-dimensional echocardiography study. *Am Heart J.* 2011;161:314–21. doi: 10.1016/j.ahj.2010.10.029

59 Lloyd-Jones DM, Wang TJ, Leip EP, *et al.* Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004;110:1042–6. doi: 10.1161/01.CIR.0000140263.20897.42

60 Bozkurt B, Coats AJS, Tsutsui H, *et al.* Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur J Heart Fail*. 2021;23:352–80. doi: 10.1002/ejhf.2115

61 Heidenreich PA, Bozkurt B, Aguilar D, *et al.* 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e895–1032. doi: 10.1161/CIR.0000000000001063

Figure and table

Figure 1. Flowchart of study participation. CAD, coronary artery disease.

Figure 2. Variable Selection Based on LASSO Regression. (A) Variation Characteristics of Variable Coefficients; (B) Selection Process of Optimal λ Value in LASSO Regression Model Using Cross-Validation.

Figure 3. Nomogram for predicting the probability of 1-, 2-, and 3-year event-free survival of ANOCA patients as assessed by coronary angiography. ALT, alanine transaminase; AST, aspartate

transaminase; LVEF, left ventricular ejection fraction.

Figure 4. Receiver operating characteristic curve for the 1-, 2-, and 3-year primary endpoints of the nomogram in the training set (A) and validation set (B). AUC, area under the curve.

Figure 5. Calibration plot of predicted 1-, 2-, and 3-year event-free survival based on the nomogram in the training set and validation set. (A–C) Training set; (D–F) Validation set.

Figure 6. Decision curve analysis of the nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the threshold probability, and the y-axis measures the net benefit. The left-slanting straight line shows the net benefit of treating all patients. The bottom horizontal gray line represents the net benefit of not treating any patients. The curve in the middle represents the nomogram.

Figure 7. Kaplan-Meier curves for primary endpoint event-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population.

Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



A



B





A



B





A



B



A



B



Supplement

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
Female, n (%)	3462 (58.3%)	2609 (58.6%)	853 (57.6%)	0.499
Age, years	43.6 (10.8)	43.7 (10.9)	43.5 (10.6)	0.563
Smoking, n (%)	1509 (25.4%)	1126 (25.3%)	383 (25.8%)	0.698
Drinking, n (%)	1883 (31.7%)	1415 (31.8%)	468 (31.6%)	0.909
Hypertension, n (%)	3698 (62.3%)	2802 (62.9%)	896 (60.5%)	0.094
Diabetes mellitus, n (%)	1123 (18.9%)	846 (19.0%)	277 (18.7%)	0.820
Diabetic complications, n (%)	19 (0.32%)	13 (0.29%)	6 (0.40%)	0.595
Dyslipidemia, n (%)	582 (9.81%)	423 (9.50%)	159 (10.7%)	0.185
CKD, n (%)	202 (3.40%)	151 (3.39%)	51 (3.44%)	0.993
SBP, mmHg	136 (19.8)	136 (19.9)	136 (19.7)	0.340
DBP, mmHg	81.9 (12.3)	81.9 (12.4)	81.8 (11.9)	0.757
Heart rate, beats/min	73.8 (15.2)	73.8 (13.9)	73.9 (18.5)	0.798
WBC, 10^9/L	6.67 (2.03)	6.68 (2.01)	6.67 (2.11)	0.969
Hemoglobin, g/L	136 (16.6)	136 (16.6)	136 (16.4)	0.881
Urea, mmol/L	6.09 (2.68)	6.09 (2.72)	6.08 (2.57)	0.831
Serum creatinine, μmol/L	65.9 [55.7; 79.8]	66.2 [55.7; 79.7]	65.4 [55.5; 80.0]	0.748
Uric acid, μmol/L	335 (100)	335 (101)	335 (99.0)	0.889
Serum sodium, mmol/L	142 (3.51)	142 (3.32)	142 (4.01)	0.829
Serum potassium, mmol/L	4.12 (0.56)	4.12 (0.47)	4.13 (0.76)	0.649
Serum chloride, mmol/L	106 (3.37)	106 (3.42)	106 (3.21)	0.515
Anion gap, mmol/L	14.0 (2.40)	13.9 (2.40)	14.0 (2.42)	0.844

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
Total protein, g/L	68.2 (6.41)	68.2 (6.37)	68.2 (6.54)	0.968
Albumin, g/L	42.4 (3.88)	42.4 (3.87)	42.3 (3.91)	0.406
Globulin, g/L	25.9 (4.19)	25.8 (4.16)	25.9 (4.30)	0.353
ALT, U/L	17.7 [13.0; 24.7]	17.8 [13.1; 24.8]	17.6 [12.6; 24.5]	0.169
AST, U/L	17.7 [14.6; 21.6]	17.8 [14.6; 21.6]	17.5 [14.6; 21.5]	0.341
ALT/AST ratio	1.06 (0.41)	1.05 (0.41)	1.07 (0.42)	0.157
Total bilirubin, μmol/L	13.6 (6.67)	13.6 (6.81)	13.4 (6.23)	0.257
Indirect Bilirubin, μmol/L	9.63 (4.69)	9.67 (4.75)	9.51 (4.53)	0.242
Direct Bilirubin, μmol/L	3.40 [2.30; 4.60]	3.40 [2.30; 4.60]	3.40 [2.40; 4.60]	0.611
Alkaline phosphatase, U/L	76.5 (23.6)	76.5 (23.6)	76.6 (23.7)	0.820
Total cholesterol, mmol/L	4.75 (1.12)	4.75 (1.13)	4.74 (1.08)	0.919
Triglycerides, mmol/L	1.63 (1.11)	1.62 (1.11)	1.65 (1.10)	0.485
HDL-C, mmol/L	1.22 (0.31)	1.22 (0.32)	1.20 (0.30)	0.083
LDL-C, mmol/L	2.97 (0.88)	2.97 (0.88)	2.98 (0.87)	0.498
VLDL-C, mmol/L	0.56 (0.37)	0.56 (0.39)	0.56 (0.30)	0.627
Troponin I, ng/ml	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.536
NT-proBNP, ng/L	83.7 [35.1; 266]	83.0 [34.3; 265]	86.7 [38.0; 269]	0.415
CKMB, U/L	12.1 [9.30; 14.7]	12.0 [9.24; 14.7]	12.3 [9.30; 14.7]	0.529
D-Dimer, μg/L	276 [2.34; 434]	274 [1.78; 427]	282 [4.65; 457]	0.110
Glucose, mmol/L	6.81 (2.48)	6.82 (2.45)	6.78 (2.56)	0.579
Left atrial diameter, mm	38.7 (5.24)	38.7 (5.28)	38.6 (5.11)	0.331

Variable	Total N=5934	Train set N=4452	Validation set N=1482	p value
LVEDD, mm	47.4 (4.46)	47.4 (4.51)	47.3 (4.28)	0.373
LVESD, mm	26.9 (5.62)	26.9 (5.65)	27.0 (5.52)	0.737
RVEDD, mm	20.8 (3.37)	20.7 (3.61)	20.8 (2.53)	0.623
LVEF, %	61.7 (6.75)	61.7 (6.77)	61.6 (6.70)	0.486
Event-free survival time, days	635 (403)	633 (402)	641 (406)	0.512
Death, n (%)	106 (1.79%)	78 (1.75%)	28 (1.89%)	0.816
MI endpoint, n (%)	33 (0.56%)	21 (0.47%)	12 (0.81%)	0.189
Stroke endpoint, n (%)	11 (0.19%)	6 (0.13%)	5 (0.34%)	0.156
MACE, n (%)	82 (1.38%)	64 (1.44%)	18 (1.21%)	0.611
Primary endpoint, n (%)	145 (2.44%)	105 (2.36%)	40 (2.70%)	0.523

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B-type natriuretic peptide; CKMB, creatine kinase-MB; LVEDD, left ventricular-end-diastolic diameter; LVESD, left ventricular-end-systolic diameter; RVEDD, right ventricular-end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACE, major adverse cardiovascular events.



Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population



Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).